INTRODUCTION
============

The thiazolidinediones (TZDs; see [Fig. 1](#fig1){ref-type="fig"}) are peroxisome proliferator--activated receptor γ (PPARγ) agonists used in the treatment of type 2 diabetes mellitus to improve target cell insulin sensitivity ([@bib52]). TZDs reduce plasma triglyceride, fatty acid, and insulin levels, increase HDL cholesterol levels, and promote adipocyte differentiation ([@bib52]; [@bib34]; [@bib90])---effects that are mediated by PPARγ-regulated gene transcription.

![TZD structures. The TZDs are hydrophobic, with octanol--water clogP values (calculated from the experimental logD~7.4~) and logD~7.4~ (experimental) of: 5.3 and 4.2 for troglitazone, 2.8 and 2.6 for rosiglitazone, 3.3 and 3.1 for pioglitazone, and 5.7 and 4.6 for ciglitazone ([@bib38]). Calculated pK*~a~* is 6.4 (±0.5) for all of the TZDs ([@bib38]). Structures were drawn using MarvinSketch 5.0.3 (ChemAxon).](JGP_201010529_RGB_Fig1){#fig1}

In addition to the PPARγ-dependent effects, TZDs have off-target effects that do not appear to involve changes in gene transcription. These effects include acute changes in cellular glucose uptake, inhibition of L-type voltage-dependent calcium channels, K~ATP~ channels, and voltage-dependent potassium channels, as well as inhibition of bile acid transport ([Table I](#tbl1){ref-type="table"}).

###### 

Membrane proteins that are modified by the TZDs

  TZD             PPARγ EC~50~[a](#tblfn1){ref-type="table-fn"}   Off-target and effect                         EC~50~[b](#tblfn2){ref-type="table-fn"}   Reference
  --------------- ----------------------------------------------- --------------------------------------------- ----------------------------------------- --------------------
                  *µM*                                                                                          *µM*                                      
  Troglitazone    0.5                                             ATP-sensitive potassium channel K~ATP~        0.7                                       [@bib64]
                                                                  L-type calcium channels                       3--4                                      [@bib77]
                                                                  Ca^2+^-activated potassium channel BK~Ca~     20--30[c](#tblfn3){ref-type="table-fn"}   [@bib61]; [@bib98]
                                                                  Delayed rectifier potassium channel Kv1.3     3                                         [@bib1]
                                                                  Acute glucose transport                       3[c](#tblfn3){ref-type="table-fn"}        [@bib86]
                                                                  Na^+^/H^+^ exchange                           10[c](#tblfn3){ref-type="table-fn"}       [@bib18]
                                                                  Bile transport (bile salt export pump)        4 10[c](#tblfn3){ref-type="table-fn"}     [@bib36]; [@bib95]
  Rosiglitazone   0.06--0.09                                      Voltage-dependent Ca^2+^ current              2[c](#tblfn3){ref-type="table-fn"}        [@bib61]
                                                                  Ca^2+^-activated potassium channels, BK~Ca~   20[c](#tblfn3){ref-type="table-fn"}       [@bib61]; [@bib98]
                                                                  Delayed rectifier potassium channel Kv1.3     18                                        [@bib1]
                                                                  Bile transport                                10[c](#tblfn3){ref-type="table-fn"}       [@bib95]
  Pioglitazone    0.6                                             L-type calcium channels                       45                                        [@bib77]
  Ciglitazone     3--23                                           Ca^2+^-activated potassium channel BK~Ca~     16                                        [@bib98]
                                                                  Store-operated calcium^+^ channels            30[c](#tblfn3){ref-type="table-fn"}       [@bib60]; [@bib23]
                                                                  Bile transport                                5[c](#tblfn3){ref-type="table-fn"}        [@bib95]

[@bib49].

Nominal concentrations, not accounting for drug distribution.

Effective concentration.

Many off-target TZD effects involve membrane proteins, which are sensitive to changes in their membrane environment ([@bib63]; [@bib5]; [@bib76]; [@bib73]), and amphiphiles tend to be potent modifiers of membrane protein function at the concentrations where they alter lipid bilayer properties ([@bib53]; [@bib71], [@bib72], [@bib73]; [@bib9]; [@bib96]; [@bib16]; [@bib55]). Because the TZDs are amphiphiles, we explored whether they alter lipid bilayer properties and thereby could modulate membrane protein function.

The "nonspecific" regulation of membrane protein function by amphiphiles occurs because of the hydrophobic and energetic coupling between bilayer-spanning proteins and their host lipid bilayer ([Fig. 2 A](#fig2){ref-type="fig"}).

![Membrane protein--lipid bilayer hydrophobic coupling. (A) Hydrophobic interactions between integral membrane proteins and their host bilayer cause the lipid bilayer (with an unperturbed hydrophobic thickness *d*~0~) and an embedded protein (with hydrophobic length *l*) to adapt to each other. Protein conformational changes that involve the protein--bilayer boundary, for example, a change in protein hydrophobic length, will alter the local bilayer thickness to match the channel length. Such local bilayer deformations, with their associated bilayer compression and monolayer bending, incur an energetic cost (the bilayer deformation energy, Δ*G*~def~). The total free energy difference between different protein conformations ($\Delta G_{\text{tot}}^{\text{I}\rightarrow{II}} = \Delta G_{\text{tot}}^{II} - \Delta G_{\text{tot}}^{\text{I}}$) therefore has a contribution not only from the protein per se ($\Delta G_{\text{prot}}^{\text{I}\rightarrow{II}} = \Delta G_{\text{prot}}^{II} - \Delta G_{\text{prot}}^{\text{I}}$) but also from the difference in bilayer deformation energy associated with the two conformations ($\Delta G_{\text{bil}}^{\text{I}\rightarrow{II}} = \Delta G_{\text{def}}^{II} - \Delta G_{\text{def}}^{\text{I}}$). The protein conformational equilibrium therefore varies as a function of the bilayer elastic moduli, protein--bilayer hydrophobic mismatch, and the intrinsic lipid curvature. (B) When amphiphiles adsorb to the bilayer--solution interface, they alter bilayer properties such as thickness (*d*~0~), intrinsic curvature (*c*~0~), and elastic moduli, as well as Δ*G*~def~. The associated changes in $\Delta G_{\text{bil}}^{\text{I}\rightarrow{II}}$ will alter the conformational preference and thus its function. (C) Bilayer-spanning gA channels form by transmembrane dimerization of two β^6.3^-helical subunits; channel formation is reported as changes in the current through the bilayer. The channel length is less than the unperturbed bilayer thickness, meaning that the energetic cost of channel formation---and the single-channel appearance frequency and lifetime---varies with changes in lipid bilayer properties. (D) Changes in lipid bilayer properties, such as those caused by the adsorption at the bilayer--solution interface, therefore will be reflected in changes in gA lifetimes and appearance frequencies, as indicated in the current trace.](JGP_201010529_RGB_Fig2){#fig2}

The insertion of a protein into a lipid bilayer will locally perturb the bilayer organization to deform the bilayer, which incurs an energetic penalty (the bilayer deformation energy, Δ*G*~def~). The difference in bilayer deformation energy between different conformations (denoted I and II) is the bilayer contribution ($\begin{matrix}
{\Delta G} \\
\end{matrix}_{\text{bil}}^{\text{I}\rightarrow{II}}$) to the free energy difference between I and II:$$\begin{matrix}
{\Delta G} \\
\end{matrix}_{\text{tot}}^{\text{I}\rightarrow{II}} = \begin{matrix}
{\Delta G} \\
\end{matrix}_{\text{prot}}^{\text{I}\rightarrow{II}} + \left( \Delta G_{\text{def}}^{II} - \Delta G_{\text{def}}^{\text{I}} \right) = \begin{matrix}
{\Delta G} \\
\end{matrix}_{\text{prot}}^{\text{I}\rightarrow{II}} + \begin{matrix}
{\Delta G} \\
\end{matrix}_{\text{bil}}^{\text{I}\rightarrow{II}}.$$

Because Δ*G*~def~, and thus $\begin{matrix}
{\Delta G} \\
\end{matrix}_{\text{bil}}^{\text{I}\rightarrow{II}},$ varies as a function of the bilayer physical properties (thickness, intrinsic monolayer curvature, and the associated elastic moduli), the protein's conformational equilibrium will vary as a function of changes in the host bilayer properties (e.g., [@bib68]; [@bib10]; [@bib73]):$$\frac{n_{II}}{n_{\text{I}}} = K^{\text{I}\rightarrow{II}} = \exp\left\{ {- \frac{\Delta G_{\text{tot}}^{\text{I}\rightarrow{II}}}{k_{\text{B}}T}} \right\} = \exp\left\{ {- \frac{\Delta G_{\text{prot}}^{\text{I}\rightarrow{II}} + \Delta G_{\text{bil}}^{\text{I}\rightarrow{II}}}{k_{\text{B}}T}} \right\},$$where *n*~I~ and *n*~II~ denote the surface densities of the proteins in state I and II, *K*^I→II^ is the equilibrium constant for the I↔II equilibrium, *k*~B~ is Boltzmann's constant, and *T* is the temperature in Kelvin.

When amphiphiles adsorb at the bilayer--solution interface, they alter many bilayer properties, including the intrinsic monolayer curvature ([@bib93]; [@bib72]) and bilayer elastic moduli ([@bib29]; [@bib110]), which will alter Δ*G*~def~ ([Fig. 2 B](#fig2){ref-type="fig"}). Changes in bilayer properties will alter membrane protein function when \|$\begin{matrix}
{\Delta G} \\
\end{matrix}_{\text{bil}}^{\text{I}\rightarrow{II}}$\| is a significant (\>*k*~B~*T*) contribution to $\begin{matrix}
{\Delta G} \\
\end{matrix}_{\text{tot}}^{\text{I}\rightarrow{II}},$ in which case changes in $\begin{matrix}
{\Delta G} \\
\end{matrix}_{\text{bil}}^{\text{I}\rightarrow{II}}$ will alter the energetics and kinetics of the I↔II equilibrium. This may provide a mechanistic basis for the widely observed "membrane effects" of many drugs ([@bib94]), including the TZDs.

To explore whether the TZDs alter lipid bilayer properties, we used the gramicidin A (gA) channels as probes ([@bib7]; [@bib73]). gA channels are dimers ([@bib12]; [@bib102]), which form by the transmembrane dimerization of nonconducting single-stranded β^6.3^-helical subunits that reside in each bilayer leaflet ([@bib83]). The kinetics of gA channel formation and disappearance is described by [@bib12], [@bib112], and [@bib88]:$$\text{M+M}\underset{\text{k}_{-1}}{\overset{\text{k}_{1}}{\rightleftharpoons}}\text{D},$$where M and D denote monomeric gA subunits (one in each bilayer leaflet) and bilayer-spanning dimers/conducting channels, and *k*~1~ and *k*~−1~ are the association and dissociation rate constants, with the channel dimerization constant (*K*~D~) given by *k*~1~/*k*~−1~. Within wide limits, the gA channel structure is remarkably unaffected by changes in bilayer environment, but the channel lifetime and appearance frequency vary with changes in bilayer thickness, elasticity, and lipid intrinsic curvature ([@bib73]). The channel function's sensitivity to changes in bilayer properties arises because the channel's hydrophobic length is less than the host bilayer's hydrophobic thickness, such that channel formation produces a local bilayer deformation with an associated deformation energy ([Fig. 2 C](#fig2){ref-type="fig"}). In response to the deformation and associated Δ*G*~def~, the bilayer exerts a disjoining force (*F*~dis~) on the dimer, and the rate constant for dimer dissociation varies with changes in *F*~dis~ (e.g., [@bib73]). The adsorption of amphiphiles at the bilayer--solution interface alters lipid bilayer elastic moduli and the monolayer-intrinsic curvature, which in turn alters *F*~dis~. These changes are observed as increased or decreased gramicidin channel lifetimes and appearance frequencies ([Fig. 2 D](#fig2){ref-type="fig"}).

The TZDs alter lipid bilayer properties, with a rank order consistent with previous reports showing troglitazone as the most potent inhibitor of ion channel function ([@bib61]; [@bib1]). They also inhibit voltage-dependent sodium channels (Na~V~). Similar to other amphiphiles ([@bib72]), the TZDs cause a hyperpolarizing shift in the steady-state availability curve. The concentration dependence of the TZDs' effects on Na~V~ is similar to that for gA channels, and the correlation between the TZD effects on gA and Na~V~ channels can be superimposed on the relation observed for other amphiphiles ([@bib72]), suggesting that some TZD off-target effects are mediated by changes in bilayer properties.

MATERIALS AND METHODS
=====================

Gramicidin experiments
----------------------

### Materials.

1,2-dioleoyl-*sn*-glycero-3-phosphocholine (DC~18:1~PC), 1,2-dieicosenoyl-*sn*-glycero-3-phosphocholine (DC~20:1~PC), 1,2-dierucoyl-*sn*-glycero-3-phosphocholine (DC~22:1~PC), and cholesterol were from Avanti Polar Lipids, Inc. *n*-Decane (99.9% pure) was from ChemSampCo. Troglitazone, rosiglitazone, and ciglitazone (≥98% purity) were from Cayman Chemical. Pioglitazone (≥99.3% purity) was from Tecoland Corporation. 8-Aminonaphthalene-1,3,6-trisulfonate (ANTS) was from Invitrogen. A chain-shortened 13--amino acid left-handed gA analogue, des-D-Val-Gly-gA^−^ (gA^−^(13)), two 15--amino acid analogues of opposite helix sense, \[Ala^1^\]gA (AgA(15)) and \[D-Ala^1^\]gA^−^ (AgA^−^(15)), and a chain-extended 17--amino acid analogue, endo-Ala^0a^-D-Ala^0b^-gA (gA(17)), were synthesized and purified as described previously ([@bib43]). Their sequences are listed in [Table S1](http://www.jgp.org/cgi/content/full/jgp.201010529/DC1).

### Single-channel current measurements.

Planar lipid bilayers were formed at 25 ± 1°C using 20-mg/ml suspensions of DC~18:1~PC, DC~18:1~PC/cholesterol (1:1 molar ratio), or DC~20:1~PC in *n*-decane across a 1--1.5-mm opening in a Teflon partition separating two 2.5-ml compartments. The chamber and electrode solutions were 1.0 M NaCl and 10 mM HEPES, pH 7. Single-channel measurements were done at ±200 mV using a patch-clamp amplifier (3900A; Dagan Corp.) and the bilayer punch method ([@bib3]; [@bib58]). The current signal was filtered at 2 kHz, sampled at 20 kHz, and digitally filtered at 500 Hz. Single-channel current transitions were identified as described previously ([@bib3]) using software written in Visual Basic (Microsoft). The gA analogues were added to both sides of the bilayer. In most experiments, we used two analogues of different length and helix sense, which allowed us to explore the role of hydrophobic mismatch. After control records were obtained, we added TZD from stock solutions (prepared in DMSO) to each side of the bilayer, stirred for 1 min, and equilibrated for 10 min. The DMSO concentration never exceeded 0.7% (vol/vol), which by itself has no effect on bilayer properties ([@bib54]).

Single-channel lifetimes (τ) were determined by fitting a single-exponential distribution (*N*(*t*)/*N*(0) = exp{−*t*/τ}, where *N*(*t*) is the number of channels with lifetimes longer than time, *t*, to the survivor histograms of the lifetime distributions using Origin 6.1 (OriginLab). The reported results are the averages of three to five experiments, each with at least 300 events. Changes in channel appearance frequency (*f*) are based on single-channel recordings (\>5 min) immediately before and immediately after adding the TZDs. Only experiments where the bilayer remained intact after TZD addition were used. The results are reported as mean ± SD; in case there are only two observations, the results are reported as mean ± range. Relative lifetime and appearance frequency changes were obtained by normalizing the values just after to those just before adding the TZD.

From the changes in the time-averaged channel density (= *f*·τ) one can calculate the changes in the channel dimerization constant (*K*~D~) as ([@bib53]):$$\frac{f_{\text{TZD}} \cdot \tau_{\text{TZD}}}{f_{\text{cntrl}} \cdot \tau_{\text{cntrl}}} = \frac{\left\lbrack D \right\rbrack_{\text{TZD}}}{\left\lbrack D \right\rbrack_{\text{cntrl}}} = \frac{k_{1,\text{TZD}} \cdot \left\lbrack M \right\rbrack_{\text{TZD}}^{\text{2}}/k_{- 1,\text{TZD}}}{k_{1,\text{cntrl}} \cdot \left\lbrack M \right\rbrack_{\text{cntrl}}^{\text{2}}/k_{- 1,\text{cntrl}}} = \frac{K_{\text{D,TZD}}}{K_{\text{D,cntrl}}},$$where the subscripts "cntrl" and "TZD" indicate the absence and presence of the TZD, and the third equality holds in the limit $\text{[M]} \gg \text{[D]}$ (when \[M\] is approximately constant). One can then calculate the changes in the free energy of dimerization ($\Delta\Delta G_{\text{tot}}^{M\rightarrow D}$) and, if the TZDs do not alter $\Delta G_{\text{prot}}^{M\rightarrow D},$ the changes in $\Delta G_{\text{bil}}^{M\rightarrow D},$ cf. [Eq. 1](#fd1){ref-type="disp-formula"}:$$\Delta\Delta G_{\text{tot}}^{M\rightarrow D} = - k_{\text{B}}T \cdot \ln\left\{ \frac{K_{\text{D},\text{TZD}}}{K_{\text{D,cntrl}}} \right\} \approx - k_{\text{B}}T \cdot \ln\left\{ \frac{f_{\text{TZD}} \cdot \tau_{\text{TZD}}}{f_{\text{cntrl}} \cdot \tau_{\text{cntrl}}} \right\} \approx \Delta\Delta G_{\text{bil}}^{M\rightarrow D},$$where the right-most relation holds when $\Delta\Delta G_{\text{prot}}^{M\rightarrow D} \approx 0.$

The capacitance of DC~18:1~PC bilayers (area, ∼1.5 mm^2^) was measured using the current response to a 2.5-Hz saw tooth potential of 10-mV peak-to-peak amplitude ([@bib70]).

### Fluorescence quench measurements.

This method has been described elsewhere ([@bib54]; [@bib56]). In brief, DC~22:1~PC in chloroform was dried and rehydrated in fluorophore (ANTS) buffer. Large unilamellar vesicles were prepared by passing the rehydrated lipid suspension through 0.1-µm membrane using a mini-extruder (Avanti Polar Lipids, Inc.), and extravesicular ANTS was removed using a desalting column (PD-10; GE Healthcare). ANTS-loaded vesicles were incubated with gA for 24 h at 12°C. The rate of ANTS fluorescence quenching by the gA channel--permeant Tl^+^ was recorded with a stopped-flow spectrofluorometer (SX.20; Applied Photophysics) with dead time of \<2 ms. Samples were excited at 352 nm, and the fluorescence signal above 455 nm was recorded. Vesicles were incubated with the TZD for 10 min at 25°C before measuring the quenching rate. TZDs are hydrophobic and cross the cell membrane to reach PPARγ; they likewise will equilibrate between the inner and the outer bilayer leaflets. Nine mixing reactions were done with each sample. Each reaction was analyzed separately using MATLAB v7.9 (The MathWorks Inc.). Quenching rates were determined by fitting the first 2--100 ms of the fluorescence time course for the individual reactions with stretched exponential ([@bib14]):$$F\left( t \right) = F\left( \infty \right) + \left( {F\left( 0 \right) - F\left( \infty \right)} \right) \cdot \exp\left\{ {- \left( t/\tau_{0} \right)^{\beta}} \right\},$$where *F*(*t*) denotes the fluorescence intensity as a function of time, *t*, τ~0~ is a parameter with units of time, and β (0 \< β ≤ 1) is a measure of the dispersity of the sample. We then determined the quenching rate at 2 ms using the expression ([@bib14]):$$k\left( t \right) = \left( {\beta/\tau_{0}} \right) \cdot \left( {t/\tau_{0}} \right)^{({\beta - 1})}.$$

The average quenching rate is the average of these rates. The reported values are averages of the quenching rates, normalized to rate in the absence of TZDs, for three or more experiments.

### Isothermal titration calorimetry.

Heats of adsorption were measured using an isothermal titration calorimeter (Auto-iTC~200~; Microcal Inc.) with 200-µl sample cell volume and 40-µl syringe volume. Large unilamellar DC~20:1~PC or DC~18:1~PC vesicles were prepared as described above, with the following modifications: the lipid rehydration buffer (150 mM NaNO~3~ and 15 mM HEPES, pH 7) did not contain ANTS, and the vesicles were not incubated with gA. TZDs were diluted from DMSO stocks with the lipid rehydration buffer. The DMSO concentration in the lipid vesicle solution was adjusted to match the TZD-containing solution.

The lipid vesicle solution was in the syringe, and the TZD solution was in the sample cell. Titration of lipid vesicles into the TZD solution was done with 2-µl injections (the first 0.2-µl injection was not taken into account during analysis). The 150-s interval between each injection allowed the signal to return to the baseline and was sufficient for equilibration of TZDs between the inner and outer bilayer leaflets. After 19 injections of 3 mM lipid into 30 µM troglitazone, or 10 mM lipid into 200 µM rosiglitazone, the lipid concentrations were 460 µM or 1.5 mM, respectively; all the TZD was considered to be bound to the lipid vesicles when the heat generation in subsequent injections became constant. (Ciglitazone and pioglitazone did not produce a measurable signal.) To control for heat of dilution of buffer and lipid vesicles, lipid vesicles were injected into a TZD-free buffer solution. The resulting enthalpies were below the detection limit of the instrument ([Fig. S9](http://www.jgp.org/cgi/content/full/jgp.201010529/DC1)); we did not correct for them in the data analysis. The enthalpy per injection was determined from the area under the curve of that injection using Origin 7 (OriginLab) as adapted by Microcal for isothermal titration calorimetry data analysis. The partition constant $K_{\text{P}}^{\text{W}\rightarrow\text{L}}$ and enthalpy of partitioning $\Delta H_{\text{P}}^{\text{W}\rightarrow\text{L}}$ were obtained by plotting the injection enthalpies versus injection number and fitting using [Eq. 7](#fd7){ref-type="disp-formula"} (derived according to [@bib105]), assuming that the process can be described as partitioning between two immiscible phases (cf., [@bib108]):$$\begin{matrix}
{\delta h_{\text{A}}\left( i \right) = \frac{i \cdot \delta V \cdot C_{\text{L}} \cdot v_{\text{L}} \cdot n_{\text{tot}}^{\text{A}} \cdot \Delta H_{\text{P}}^{\text{W}\rightarrow\text{L}} \cdot K_{\text{P}}^{\text{W}\rightarrow\text{L}}}{V_{\text{W}}\left( 0 \right) + i \cdot \delta V \cdot \left( {1 + C_{\text{L}} \cdot v_{\text{L}} \cdot K_{\text{P}}^{\text{W}\rightarrow\text{L}}} \right)}} \\
{- \frac{\left( i - 1 \right) \cdot \delta V \cdot C_{\text{L}} \cdot v_{\text{L}} \cdot n_{\text{tot}}^{\text{A}} \cdot \Delta H_{\text{P}}^{\text{W}\rightarrow\text{L}} \cdot K_{\text{P}}^{\text{W}\rightarrow\text{L}}}{V_{\text{W}}\left( 0 \right) + \left( i - 1 \right) \cdot \delta V \cdot \left( {1 + C_{\text{L}} \cdot v_{\text{L}} \cdot K_{\text{P}}^{\text{W}\rightarrow\text{L}}} \right)}} \\
{\approx \frac{\delta V \cdot C_{\text{L}} \cdot v_{\text{L}} \cdot n_{\text{tot}}^{\text{A}} \cdot V_{\text{W}}\left( 0 \right) \cdot \Delta H_{\text{P}}^{\text{W}\rightarrow\text{L}} \cdot K_{\text{P}}^{\text{W}\rightarrow\text{L}}}{\left( {V_{\text{W}}\left( 0 \right) + \left( i - 0.5 \right) \cdot \delta V \cdot \left( {1 + C_{\text{L}} \cdot v_{\text{L}} \cdot K_{\text{P}}^{\text{W}\rightarrow\text{L}}} \right)} \right)^{2}},} \\
\end{matrix}$$where ***i*** is the injection number, $\delta h_{\text{A}}\left( i \right)$ the injection enthalpy, δ*V* is the injection volume, *C*~L~ is the lipid concentration, ν~L~ is the molar lipid volume, $n_{\text{tot}}^{\text{A}}$ is the amount of amphiphile in moles, and *V*~W~(0) is the initial cell volume. Knowing $K_{\text{P}}^{\text{W}\rightarrow\text{L}}$ and $\Delta H_{\text{P}}^{\text{W}\rightarrow\text{L}}$ (assuming Δ*H*~P~ is measurable), the free energy ($\Delta G_{\text{P}}^{\text{W}\rightarrow\text{L}}$) and entropy ($\Delta S_{\text{P}}^{\text{W}\rightarrow\text{L}}$) of partitioning is calculated as $\Delta G_{\text{P}}^{\text{W}\rightarrow\text{L}} = \Delta H_{\text{P}}^{\text{W}\rightarrow\text{L}} + T \cdot \Delta S_{\text{P}}^{\text{W}\rightarrow\text{L}},$ where $\Delta G_{\text{P}}^{\text{W}\rightarrow\text{L}} = - RT\ln\left( K_{\text{P}}^{\text{W}\rightarrow\text{L}} \right).$

Sodium channel current measurements
-----------------------------------

### Cell culture.

The ND7/23 rat dorsal root ganglion/mouse neuroblastoma fusion cell line (Sigma-Aldrich) was cultured in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 10% (vol/vol) fetal bovine serum (Invitrogen), 2 mM [l]{.smallcaps}-glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin (Invitrogen) at 37°C under 95% air/5% CO~2~. Cells were grown on 12-mm glass coverslips in 35-mm polystyrene culture dishes and used within 48--72 h of plating.

### Electrophysiology.

Endogenous TTX-sensitive Na^+^ currents (ND7/23 cells express a combination of Na~V~ subtypes 1.1, 1.2, 1.6, and 1.7, as shown by Western blotting; not depicted) were recorded using the whole cell clamp configuration ([@bib44]). Coverslips containing ND7/23 cells were transferred into a small-volume open bath chamber (Warner Instruments) and continuously perfused at ∼2 ml/min with a solution containing (in mM): 130 NaCl, 10 HEPES, 3.25 KCl, 2 MgCl~2~, 2 CaCl~2~, 20 TEACl, and 5 [d]{.smallcaps}-glucose, adjusted to pH 7.4 (with NaOH), and 310 mOsm/kg H~2~O (with sucrose).

Voltage-clamp recordings were done at room temperature (23--24°C) using a patch-clamp amplifier (Axopatch 200B; Molecular Devices) with a sampling rate of 20- and 5-kHz low-pass filter. Recording pipettes were pulled from borosilicate glass capillaries (Sutter Instrument) on a puller (P-97; Sutter Instruments) and fire-polished. The pipettes were filled with a solution containing (in mM): 120 CsF, 10 NaCl, 10 HEPES, 10 EGTA, 10 TEACl, 1 CaCl~2~, and 1 MgCl~2~, adjusted to pH 7.3 (with CsOH), and 310 mOsm/kg H~2~O (with sucrose). The pipettes had a tip resistance of 1.5--2.5 MΩ. The access resistance, 2--4 MΩ, was further decreased using 70--80% series resistance compensation. The initial whole cell seal resistance was 2--4 GΩ, and recordings were discarded if the resistance dropped below 1 GΩ. Liquid--junction potentials were not corrected. Capacitive current transients were electronically cancelled with the internal amplifier circuitry, and leak currents were digitally subtracted online using the P/4 protocol ([@bib15]).

The TZDs dissolved in DMSO were diluted in the external perfusion buffer to their final concentration before experiments the same day. Final DMSO concentrations did not exceed 0.7% (vol/vol). (1% DMSO has no effect on activation or inactivation; not depicted.) The perfusion system consisted of Teflon tubing connected to a 200-µm diameter perfusion pipette positioned in close proximity to the patch-clamped cell. The perfusion rate was ∼0.2 ml/min and controlled by a pressurized perfusion system (ALA Scientific Instruments).

### Stimulation protocols and data analysis.

The holding potential (*V*~h~) was −80 mV unless otherwise stated. Voltage-dependent inhibition of peak inward Na^+^ current (*I*~Na~) by TZDs was analyzed using a 10-ms test pulse to 0 mV preceded by a 300-ms prepulse alternating to either −130 mV (*V*~0~) or the voltage of half-maximal inactivation (*V*~1/2~ = −68 ± 5 mV), applied every 5 s ([@bib71]). *V*~1/2~ was determined for each cell using the two-pulse protocol described below.

For examining Na^+^ channel activation, currents were evoked by a series of 10-ms pulses ranging from −60 to +70 mV in 10-mV steps every 5 s. The conductance (*G*~Na~) was calculated as *G*~Na~ = *I*~Na~/(*V*~m~ − *E*~rev~), where *I*~Na~ is the peak inward current, *V*~m~ is the amplitude of the voltage step, and *E*~rev~ is the reversal potential (about +65 mV), as estimated using the Nernst equation and the internal and external Na^+^ concentrations of 10 and 130 mM, respectively; the recorded *E*~rev~ varied between 65 and 68 mV and did not change with TZD application (not depicted). The normalized conductance (*G*/*G*~max~, where *G*~max~ is the maximal conductance) was plotted versus*V*~m~ and fitted with a Boltzmann function:$$G/G_{\text{max}} = 1/\left( {1 + \exp\left\{ {- e \cdot z_{\text{a}} \cdot \left( V_{\text{m}} - V_{\text{a}} \right)/k_{\text{B}}T} \right\}} \right),$$where *V*~a~ is the potential for half-maximal activation, *e* is the elementary charge, and *z*~a~ is the apparent gating valence.

Steady-state fast inactivation, or "Na^+^ channel availability," *h*~∞~ in [@bib50], was measured using a double-pulse protocol with a 300-ms prepulse ranging from −130 to −10 mV in 10-mV steps, followed by a test pulse to 0 mV. Peak currents during the test pulse were normalized to the maximal current (*I*/*I*~max~, where *I*~max~ is the maximal current that is elicited at the test potential), plotted versus the prepulse potential (*V*~m~), and fitted with a Boltzmann function:$$I/I_{\text{max}} = 1/\left( {1 + \exp\left\{ {- e \cdot z_{\text{1/2}} \cdot \left( V_{\text{m}} - V_{\text{1/2}} \right)/k_{\text{B}}T} \right\}} \right),$$where *z*~1/2~ and *V*~1/2~ denote the apparent gating valence and potential for half-maximal inactivation.

Statistical significance was assessed by two-tailed paired Student's *t* test. P \< 0.05 was considered statistically significant. Programs used for data acquisition and analysis were pClamp 10 (Molecular Devices), Excel (Microsoft), and Prism 5.0 (GraphPad Software Inc.). Values are reported as mean ± SD unless otherwise stated.

Online supplemental material
----------------------------

Fig. S1 shows TZD's effects on gA single-channel currents. Fig. S2 shows ciglitazone's effects on gA single-channel currents at pH 6, 7, and 8. Fig. S3 shows pioglitazone's effects on gA function at pH 6. Fig. S4 shows TZD effects on gA channel lifetimes. Fig. S5 shows changes in gA^−^(13) lifetimes relative to changes in AgA(15) lifetimes in the presence of TZDs. Fig. S6 shows relative lifetimes of gA^−^(15) and gA(17) in DC~20:1~PC bilayers as function of \[ciglitazone\]. Fig. S7 compares the effects of troglitazone and ciglitazone on gA activity in the presence and absence of cholesterol in DC~18:1~PC bilayers. Fig. S8 shows fluorescence quenching traces from stopped-flow experiments with ciglitazone and troglitazone. Fig. S9 shows dilution enthalpies of lipid in TZD-free buffer solution. Fig. S10 shows timed control experiments for the Na~V~ inactivation experiments. Fig. S11 shows ciglitazone's effects on gA single-channel currents in DC~20:1~PC bilayers. Table S1 lists the sequences of the gA analogues used in this study. Table S2 lists the Na~V~ peak current inhibition, Table S3 lists the V~1/2~ of steady-state inactivation, and Table S4 lists the V~1/2~ of activation before, during, and after TZD superfusion.

RESULTS
=======

Gramicidin experiments
----------------------

### TZDs alter gA channel function.

The TZD effects on gA channel function were examined by comparing the gA single-channel properties before and after the addition of each TZD. The left-handed 13--amino acid gA^−^(13) and the right-handed 15--amino acid AgA(15) analogues form channels with characteristic current transition amplitudes, marked in [Fig. 3 A](#fig3){ref-type="fig"} by red and blue lines for gA^−^(13) and AgA(15), respectively. (Because the two analogues form channels having opposite handedness, they do not form heterodimers.) [Fig. 3 (A--D)](#fig3){ref-type="fig"} shows single-channel activity before and after the addition of each TZD.

![TZD-induced changes in gA function. Current traces before and after the addition of each of the four TZDs to both sides of a DC~18:1~PC/*n*-decane bilayer doped with gA^−^(13) and AgA(15). In each panel, the top trace was recorded before adding the TZD, and the bottom trace was recorded after the addition. The colored lines denote the current levels for gA^−^(13) (red line) and AgA(15) (blue line). The four panels show the effects of: (A) 1 µM troglitazone, (B) 30 µM rosiglitazone, (C) 10 µM pioglitazone, and (D) 6 µM ciglitazone. Bars, 3 pA and 30 s.](JGP_201010529_RGB_Fig3){#fig3}

Troglitazone rosiglitazone and pioglitazone increase gA channel activity, the time-averaged number of channels ([Fig. 3, A--C](#fig3){ref-type="fig"}); 6 µM ciglitazone decreased the activity of both gA^−^(13) and AgA(15) channels (bottom trace in [Fig. 3 D](#fig3){ref-type="fig"}). The TZDs are potent modifiers of gA channel function, with effects that vary among the compounds tested.

### Changes in gA single-channel properties.

The changes in gA channel activity reflect changes in the energetics of gA channel formation. To characterize these changes, we examined the TZDs' effects on gA single-channel current transition amplitudes, lifetimes, and appearance frequencies. The current transition amplitude histograms ([Fig. 4, A and B](#fig4){ref-type="fig"}, and [Fig. S1](http://www.jgp.org/cgi/content/full/jgp.201010529/DC1)), show that TZDs---except for ciglitazone, which caused a modest increase ([Fig. 4 B](#fig4){ref-type="fig"})---did not alter the conductances of gA^−^(13) or AgA(15) channels at the highest concentrations tested. The lack of effect on the gA single-channel conductance suggests that troglitazone, rosiglitazone, and pioglitazone do not bind to, or otherwise interact directly with, gA channels.

![Effects of TZDs on ion permeation and single-channel lifetimes. Current transition amplitude histograms for gA^−^(13) and AgA(15) channels before (control) and after the addition of: (A) 6 µM troglitazone (TRO) and (B) 6 µM ciglitazone (CIG). The vertical lines denote the single-channel current transition amplitudes in the absence of the TZD for gA^−^(13) (red line) and AgA(15) (blue line). Single-channel survivor histograms for gA^−^(13) (red line) and AgA(15) (blue line) channels in the presence of varying concentrations of: (C) troglitazone (TRO) and (D) ciglitazone (CIG). Each plot was fitted with a single-exponential distribution (dashed gray lines); the average lifetimes (τ) for each TZD and concentration are indicated in the panels.](JGP_201010529_RGB_Fig4){#fig4}

The conductance changes caused by ciglitazone could reflect that ciglitazone is a weak acid (pK of ∼6.4; [@bib38]). Adsorption of the anionic form of ciglitazone at the bilayer/solution would increase the local \[Na^+^\], and thus the single-channel conductance ([@bib8]). If so, the ciglitazone-induced conductance should be pH dependent, which it is; at pH 8, the conductance increase was greater than at pH 7, and at pH 6, there was no conductance increase ([Fig. S2](http://www.jgp.org/cgi/content/full/jgp.201010529/DC1)). These results suggest that the conductance changes occur because the anionic form of ciglitazone adsorbs at the bilayer--solution interface and effectively excludes that the conductance changes are a result of changes in the interfacial dipole potential. We also examined whether similar pH-dependent conductance changes occurred with pioglitazone. They did not ([Fig. S3](http://www.jgp.org/cgi/content/full/jgp.201010529/DC1)). We do not understand why only ciglitazone alters the single-channel conductance

Troglitazone increased the lifetimes (τ) of both gA^−^(13) and AgA(15) channels with a 50% increase at 1 µM ([Figs. 4 C](#fig4){ref-type="fig"} and [5 A](#fig5){ref-type="fig"}). Rosiglitazone caused similar increases in τ, but at 30-fold higher concentrations ([Figs. S4 B](http://www.jgp.org/cgi/content/full/jgp.201010529/DC1) and [5 B](#fig5){ref-type="fig"}). Pioglitazone did not alter τ at concentrations up to 10 µM, its solubility limit (Figs. S4 C and [5 C](#fig5){ref-type="fig"}). Ciglitazone caused moderate increases in τ at concentrations up to 6 µM, where the effect appears to saturate ([Figs. 4 D](#fig4){ref-type="fig"} and [5 D](#fig5){ref-type="fig"}). (The ciglitazone-induced changes in τ did not vary as a function of pH; not depicted.)

![TZD-induced changes in single-channel lifetime and appearance frequency. Relative changes in gA^−^(13) (red squares) and AgA(15) (blue circles) channel lifetimes as a function of \[TZD\], normalized to the lifetimes before TZD addition for: (A) troglitazone (TRO), (B) rosiglitazone (ROS), (C) pioglitazone (PIO), and (D) ciglitazone (CIG; *n* = 4--7). The appearance frequency after is normalized to the appearance frequency before the addition of the TZD: (E) 1 µM troglitazone (TRO), (F) 30 µM rosiglitazone (ROS), (G) pioglitazone (PIO), and (H) ciglitazone (CIG; *n* = 2--4).](JGP_201010529R_RGB_Fig5){#fig5}

Similar to many other amphiphiles ([@bib72]), troglitazone, rosiglitazone, and ciglitazone caused larger relative increases in τ of gA^−^(13) as compared with AgA(15) channels ([Fig. S5, A, B, and D](http://www.jgp.org/cgi/content/full/jgp.201010529/DC1)). We return to this below.

The TZDs also alter the channel appearance frequencies (*f*) ([Fig. 3](#fig3){ref-type="fig"}). The changes in *f* were evaluated in experiments in which the bilayer did not break during/after the addition of the TZD ([Fig. 5, E--H](#fig5){ref-type="fig"}), which limits our ability to explore changes caused by troglitazone and rosiglitazone above 1 and 30 µM, respectively, because bilayers break upon the addition of higher concentrations. 1 µM troglitazone ([Fig. 5 E](#fig5){ref-type="fig"}), 30 µM rosiglitazone ([Fig. 5 F](#fig5){ref-type="fig"}), and 10 µM pioglitazone ([Fig. 5 G](#fig5){ref-type="fig"}) increased *f* for gA^−^(13) and AgA(15) channels, with the larger effect on the shorter gA^−^(13) channels. 6 µM ciglitazone reduced *f* for gA^−^(13) channels to ∼50% of control with little effect on AgA(15) channels ([Fig. 5 H](#fig5){ref-type="fig"}). This effect is, at least in part, dependent on channel--bilayer hydrophobic mismatch, as ciglitazone reduced *f* for AgA^−^(15) channels in DC~20:1~PC/*n*-decane bilayers (not depicted).

Troglitazone and rosiglitazone had larger effects on *f* ([Fig. 5, E and F](#fig5){ref-type="fig"}) than on τ ([Fig. 5, A and B](#fig5){ref-type="fig"}), reflecting the greater sensitivity of the gA dimerization rate constant, as compared with the dissociation rate constant, to changes in bilayer properties ([@bib72]).

### The TZDs alter lipid bilayer properties.

The results in [Figs. 3](#fig3){ref-type="fig"}--[5](#fig5){ref-type="fig"} show that the TZDs alter gA channel function. The TZDs have quantitatively similar effects on left- and right-handed gA channels ([Fig. 5](#fig5){ref-type="fig"}), and when plotting ln{τ/τ~cntrl~}, where "cntrl" denotes results in the absence of amphiphile, for gA^−^(13) channels versus ln{τ/τ~cntrl~} for AgA(15) channels ([Fig. 6](#fig6){ref-type="fig"}), the results for the TZDs and structurally unrelated compounds ([@bib74]) are described by a shared linear relation with a slope of ∼1.2. That is, the TZDs conform to the pattern observed with other bilayer-modifying amphiphiles, indicating that all of these compounds alter the lifetimes by a common mechanism.

![Changes in gA^−^(13) channel lifetimes (τ~13~) as a function of the corresponding changes in AgA(15) channel lifetimes (τ~15~). Gray data are from [@bib74]. The colored results are from this study; each point represents the average value from two to seven experiments. Color code: olive, troglitazone (TRO); pink, rosiglitazone (ROS); orange, ciglitazone (CIG); gray, pioglitazone (PIO). Linear fit (solid line) to the data points has a slope of 1.24 (*r* = 0.997).](JGP_201010529R_RGB_Fig6){#fig6}

This commonality shows that these compounds act through a common mechanism and excludes that they alter τ through direct interactions with the bilayer-spanning β^6.3^-helical dimers. Because amphiphiles alter lipid bilayer properties, including their elastic moduli (e.g., [@bib29]; [@bib110]; [@bib75]; [@bib111]), the most likely common mechanism is that the TZD, like other amphiphiles, alter gA channel lifetimes by altering lipid bilayer properties.

The situation is more complicated, however. Although the ciglitazone-induced changes in τ are consistent with bilayer-mediated mechanism ([Fig. 6](#fig6){ref-type="fig"}), no change in *f* of AgA(15) channels and a decrease in *f* for gA^−^(13) channels indicate that this compound has additional effects. The decreased appearance frequency (for the gA^−^(13) channels) could reflect a shift in the equilibrium between conducting single-stranded and nonconducting double-stranded dimers ([@bib99]; [@bib42]; [@bib37]), or a shift between different monomeric conformers. We explored this using size-exclusion chromatography (SEC) and found no effect on the distribution between single-stranded and double-stranded conformers (Kapoor, R., personal communication). We conclude that ciglitazone does not have specific interactions with the bilayer-spanning single-stranded β^6.3^-helical gA dimers. Pioglitazone did not alter τ at the concentrations tested ([Fig. 5 C](#fig5){ref-type="fig"}), most likely reflecting its limited solubility and rather low logP, and consequently low membrane concentration. Yet, pioglitazone increases *f* with similar effects on right- and left-handed channels ([Fig. 5 G](#fig5){ref-type="fig"}). We do not understand why, but note that pioglitazone is completely inert in cholesterol-containing bilayers (see below), effectively excluding specific pioglitazone--gA interactions.

### The TZDs do not alter bilayer thickness.

The TZD-induced changes in gA channel function could result from changes in bilayer thickness. Bilayer thinning will result in capacitance increase $C_{\text{m}} = \varepsilon_{0}\varepsilon_{\text{r}}/d_{0},$ where *C*~m~ is the specific capacitance of the bilayer, ε*~o~* is the permittivity of free space, ε*~r~* is the relative dielectric constant, and *d*~0~ is the bilayer hydrophobic thickness. We determined the TZDs' effects on *C*~m~ of DC~18:1~PC bilayers. Troglitazone (mean ± SD: control, 4.8 ± 0.3 nF/mm^2^; 10 µM troglitazone, 4.9 ± 0.2 nF/mm^2^), rosiglitazone (control, 4.8 ± 0.2 nF/mm^2^; 100 µM rosiglitazone, 4.7 ± 0.3 nF/mm^2^), and pioglitazone (control, 4.9 ± 0.1 nF/mm^2^; 10 µM pioglitazone, 4.9 ± 0.1 nF/mm^2^) did not increase *C*~m~, demonstrating that the increases in τ and *f* do not result from bilayer thinning. 6 µM ciglitazone increased *C*~m~ ∼16% (C~m~ ± SD: control, 4.9 ± 0.2 nF/mm^2^; 6 µM ciglitazone, 5.7 ± 0.2 nF/mm^2^).

The modest ciglitazone-induced increase in τ is not consistent with the bilayer thinning predicted from the capacitance increase. Rather, ciglitazone may act like a hydrophobic anion and increase the membrane capacitance by intramembrane charge transfer ([@bib31]). Indeed, ciglitazone increases the bilayer conductance. 10 µM ciglitazone increases the steady-state conductance from 10^−8^ S/cm^2^ to 4 × 10^−8^ S/cm^2^, consistent with an aqueous diffusion-limited current ([@bib62]). This effect seems to be specific for ciglitazone; 6 µM troglitazone had no effect on the bilayer conductance.

### The TZDs alter the energetics of gA dimerization and lipid bilayer elasticity.

To minimize the exposure of hydrophobic residues to water, gA channels and their host bilayer are coupled though hydrophobic interactions, and the formation of gA channels of hydrophobic length (*l*) in a bilayer of hydrophobic thickness (*d*~0~) causes a local change in bilayer thickness, a thinning because *l* is less than *d*~0~ ([Fig. 2, C and D](#fig2){ref-type="fig"}). Changes in the energetics of the associated bilayer deformation ([@bib51]; [@bib48]; [@bib80]; [@bib79]; [@bib84]) will alter the kinetics and energetics of gA channel formation ([@bib73]).

From the changes in *f* (= *k*~1~·\[M\]^2^) and τ (= 1/ *k*~−1~), one can calculate the changes in the time-averaged channel density, *K*~D~ (see Materials and methods). [Table II](#tbl2){ref-type="table"} summarizes the TZD-induced changes in *f*·τ and $\Delta\Delta G_{\text{tot}}^{\text{M}\rightarrow\text{D}}$ for troglitazone, rosiglitazone, pioglitazone, and ciglitazone. In the case of troglitazone and rosiglitazone, the TZDs appear to act through a bilayer-mediated mechanism (meaning that$\Delta\Delta G_{\text{prot}}^{\text{M}\rightarrow\text{D}} \approx 0$) and $\Delta\Delta G_{\text{bil}}^{\text{M}\rightarrow\text{D}} \approx \Delta\Delta G_{\text{tot}}^{\text{M}\rightarrow\text{D}}.$

###### 

TZD induced changes in the free energy of dimerization of gA channels

  TZD                   $\Delta G_{\text{tot\ gA-(13)}}^{\text{M}\rightarrow\text{D}}$   SD     $\Delta G_{\text{tot\ AgA(15)}}^{\text{M}\rightarrow\text{D}}$   SD
  --------------------- ---------------------------------------------------------------- ------ ---------------------------------------------------------------- -----
  1 µM troglitazone     −5.0                                                             0.60   −4.0                                                             0.8
  30 µM rosiglitazone   −5.0                                                             0.2    −4.0                                                             0.9
  10 µM pioglitazone    −4.6                                                             1.2    −4.2                                                             1.3
  6 µM ciglitazone      1.7                                                              1.7    −0.6                                                             2.4

Results in kJ/mole, *n* = 2--4.

In response to the bilayer deformation and associated $\Delta G_{\text{bil}}^{\text{M}\rightarrow\text{D}},$ the bilayer exerts a disjoining force (*F*~dis~) on the channels. *F*~dis~ varies a function of the hydrophobic mismatch (*d*~0~ − *l*), the elastic coefficients *H*~B~ and *H*~X~, and the intrinsic monolayer curvature *c*~0~ (see [Eq. A5](#fda5){ref-type="disp-formula"}):$$F_{\text{dis}} = 2 \cdot H_{\text{B}} \cdot \left( {d_{0} - l} \right) - H_{\text{X}} \cdot c_{0}.$$

The relative increases in τ for the gA^−^(13) channels were larger than for the AgA(15) channels (Figs. S5 A, B, and D, and [6](#fig6){ref-type="fig"}), meaning that the hydrophobic mismatch-dependent term in [Eq. 10](#fd10){ref-type="disp-formula"} contributes to the changes in *F*~dis~ (and $\Delta G_{\text{bil}}^{\text{M}\rightarrow\text{D}}$). Changes in *H*~B~·(*l* − *d*~0~) could be a result of changes in *H*~B~ or *d*~0~ (the gA channel structure, and thus *l*, is insensitive to changes in bilayer thickness; [@bib103]; [@bib59]). The changes in *H*~B~ can be estimated by comparing the relative change in the lifetimes of the longer and shorter channels ([@bib73]):$$\frac{\tau_{15}^{\text{cntrl}} \cdot \tau_{13}^{\text{TZD}}}{\tau_{15}^{\text{TZD}} \cdot \tau_{13}^{\text{cntrl}}} = \exp\left\{ \frac{\begin{matrix}
{2 \cdot \delta \cdot \left( H_{\text{B}}^{\text{TZD}} - H_{\text{B}}^{\text{cntrl}} \right) \cdot \left( l_{2} - l_{1} \right)} \\
\end{matrix}}{k_{\text{B}}T} \right\},$$where the subscripts 13 and 15 denote the two channel types. Using [Eq. 11](#fd11){ref-type="disp-formula"}, we find that 6 µM troglitazone and 200 µM rosiglitazone decrease *H*~B~ by ∼4 kJ/(mole·nm^2^) or ∼1.6 *k*~B~*T*/nm^2^; 1 µM troglitazone and 30 µM rosiglitazone decrease *H*~B~ by ∼1.5 kJ/ (mole·nm^2^) or ∼0.6 *k*~B~*T*/nm^2^. These changes in bilayer elasticity, although small compared with *H*~B~ for DC~18:1~PC/*n*-decane bilayers (56 kJ/(mole·nm^2^) or 22.6 *k*~B~*T*/nm^2^; [@bib73]), are sufficient to account for the changes in bilayer deformation energy (see Discussion). (Similar estimates were not possible for pioglitazone and ciglitazone because the lifetime changes were small, and the estimates were susceptible to even minor experimental noise. The ciglitazone-induced changes in τ, however, are a result of changes in bilayer elasticity, as evident from the larger changes in τ of the gA^−^(13) channels, relative to the AgA(15) channels \[[Figs. 5 D](#fig5){ref-type="fig"}, S5 D, and [6](#fig6){ref-type="fig"}\], and from the larger changes in τ of the AgA(15) channels in the thicker DC~20:1~PC/*n*-decane bilayers \[[Fig. S6](http://www.jgp.org/cgi/content/full/jgp.201010529/DC1)\], as compared with the DC~18:1~PC/*n*-decane bilayers \[[Fig. 5 D](#fig5){ref-type="fig"}\].)

### Effects of cholesterol.

We tested the most and least potent bilayer-modifying TZDs (troglitazone and pioglitazone) in cholesterol-containing bilayers. Cholesterol increases the bilayer elastic moduli ([@bib26]; [@bib27]; [@bib78]), meaning that the bilayers are more difficult to deform ([@bib26]; [@bib70]). Similarly to what was found with polyunsaturated fatty acids ([@bib16]), troglitazone has greater effects on gA lifetime ([Fig. S8 A](http://www.jgp.org/cgi/content/full/jgp.201010529/DC1)) and appearance frequency (Fig. S8 B) in cholesterol-containing bilayers. Pioglitazone, which had no effect on τ in cholesterol-free bilayers, changed neither τ ([Fig. S7 A](http://www.jgp.org/cgi/content/full/jgp.201010529/DC1)), *f* (Fig. S7 B), nor $\Delta G_{\text{bil}}^{\text{M}\rightarrow\text{D}}$ (Fig. S7 C).

### TZD effects in hydrocarbon-free bilayers.

Planar bilayers used in the electrophysiological experiments contain decane. We also did experiments in hydrocarbon-free lipid vesicles, using a fluorescence-based assay for gA channel activity ([@bib54]). To monitor gA channel activity, ANTS-loaded large unilamellar vesicles are mixed with Tl^+^, and the time course of fluorescence quenching is recorded (Fig. S8). The resulting quenching rate provides a measure of the time-averaged number of channels in the vesicles. Except for ciglitazone, the TZDs increased the quenching rates, with troglitazone being the most potent and pioglitazone the least ([Fig. 7](#fig7){ref-type="fig"}). Ciglitazone reduced the quenching rate, indicating that the (hydrophobic mismatch--dependent) reduction in channel appearance rate ([Fig. 5 H](#fig5){ref-type="fig"}) dominates over the increase in channel lifetime ([Fig. 5 D](#fig5){ref-type="fig"}), leading to an overall reduction in channel activity.

![Effects of TZDs on the rate of Tl^+^-induced fluorescence quenching of ANTS encapsulated in large unilamellar vesicles. ANTS-containing DC~22:1~PC vesicles doped with gA were incubated for 10 min at 25°C with troglitazone (TRO, olive squares), rosiglitazone (ROS, pink squares), pioglitazone (PIO, gray squares), or ciglitazone (CIG, orange squares) before mixing with Tl^+^ using a stopped-flow spectrofluorometer. The quench rate was determined by fitting a stretched exponential to the time course of fluorescence quenching and determining the rate at 2 ms. Quench rates in the presence of the TZD are normalized to control quench rate in the absence of TZDs (*n* = 2--10).](JGP_201010529R_RGB_Fig7){#fig7}

The relative increases in quenching rates follow the pattern observed in the single-channel experiments ([Fig. 5](#fig5){ref-type="fig"}), and the effective concentration ranges and the order of TZD potencies are the same in both systems. The three TZDs that increase channel activity increase the quench rate; ciglitazone, which decreases channel activity, decreases the quench rate. The effects of the TZDs in hydrocarbon-free membranes are comparable to their effects in the presence of decane.

### TZD partitioning into lipid bilayers.

Hydrophobicity, as measured by octanol--water partitioning (logP: partitioning of only a single, usually the neutral, species; or logD~7.4~: distribution of all species present at pH 7.4), varies among the TZDs, with troglitazone and ciglitazone being the most hydrophobic, followed by pioglitazone and rosiglitazone (legend to [Fig. 1](#fig1){ref-type="fig"}). LogP (or logD) thus provides a good estimate for the partition coefficient of neutral, but not charged, solutes into lipid bilayers ([@bib24]). For the weakly acidic TZDs, pK*~a~* values of ∼6.4 ([@bib38]), the different electrostatic properties of the bilayer interface and the octanol--water phase may cause clogP (and logD~7.4~) to be poor predictors of TZD partitioning into bilayers. (pK*~a~* of the adsorbed TZDs is likely to be higher than the bulk pK*~a~* \[cf. [@bib85]\], and it is unclear what fraction of the TZDs at the bilayer--solution interface is charged.) We therefore examined the interactions of TZDs with lipid bilayers using isothermal titration calorimetry ([@bib47]).

Only rosiglitazone and troglitazone produced sufficient heats of partitioning to determine $K_{\text{P}}^{\text{W}\rightarrow\text{L}}.$ [Fig. 8 A](#fig8){ref-type="fig"} (left) shows the titration of 200 µM rosiglitazone with 10-mM lipid vesicles (the lipid vesicle dilution enthalpy is negligible \[Fig. S9\] and is not considered in the data analysis).

![Partitioning of troglitazone and rosiglitazone into lipid bilayers. (A) Heat production as a function of time as 2-µl aliquots of a 10-mM lipid vesicle solution is injected into 200 µM of rosiglitazone solution. Each injection results in a peak in the energy versus time signal (left); the area under the peak corresponds to the enthalpy of partitioning for that injection, which is plotted as a function of the injection number (▪, right panel). The solid line denotes the fit of [Eq. 7](#fd7){ref-type="disp-formula"} to the results to determine the partition coefficient ($K_{\text{P}}^{\text{W}\rightarrow\text{L}}$) and the molar enthalpy of partitioning ($\Delta H_{\text{P}}^{\text{W}\rightarrow\text{L}}$). (The partitioning of troglitazone was tested by titrating 30 µM troglitazone with 3 mM lipid.) (B) The partition coefficient $K_{\text{P}}^{\text{W}\rightarrow\text{L}}$ (solid fill bars) and $\log K_{\text{P}}^{\text{W}\rightarrow\text{L}}$ (hatched fill bars) for troglitazone (olive) and rosiglitazone (pink). (C) $\Delta G_{\text{P}}^{\text{W}\rightarrow\text{L}}$ (dark filled bars), $\Delta H_{\text{P}}^{\text{W}\rightarrow\text{L}}$ (light filled bars), and $T\Delta S_{\text{P}}^{\text{W}\rightarrow\text{L}}$ (open bars) for troglitazone (TRO, pink) and rosiglitazone (ROS, pink). *n* = 3; error bars are plotted.](JGP_201010529_RGB_Fig8){#fig8}

Plotting the enthalpy per injection versus the injection number ([Fig. 8 A](#fig8){ref-type="fig"}, right) and fitting [Eq. 7](#fd7){ref-type="disp-formula"} to the results allows for determining $K_{\text{P}}^{\text{W}\rightarrow\text{L}}$ ([Fig. 8 B](#fig8){ref-type="fig"}) and $\Delta H_{\text{P}}^{\text{W}\rightarrow\text{L}},$ $\Delta G_{\text{P}}^{\text{W}\rightarrow\text{L}},$ and $T \cdot \Delta S_{\text{P}}^{\text{W}\rightarrow\text{L}}$ ([Fig. 8 C](#fig8){ref-type="fig"}). Log $K_{\text{P}}^{\text{W}\rightarrow\text{L}}$ for both rosiglitazone (3.2) and troglitazone (4.5) were higher than the corresponding LogD~7.4~ (legend to [Fig. 1](#fig1){ref-type="fig"}). The thermodynamic profile for the partitioning of troglitazone differed from that for rosiglitazone, with entropy dominating the former and enthalpy the latter, which could reflect different locations within the bilayer--solution interface.

TZD effects on Na~V~ on cell membranes
--------------------------------------

### Voltage-dependent inhibition of Na^+^ currents (*I*~Na~).

As noted above ([Table I](#tbl1){ref-type="table"}), the TZDs modulate a variety of membrane proteins. We explored this question further using endogenous TTX-sensitive sodium currents in ND7/23 cells. We have previously found that amphiphiles that alter gA channel function (increase *f* and τ) also alter the function of voltage-dependent calcium and sodium channels (Na~V~) ([@bib70], [@bib71], [@bib72]). We therefore explored whether the TZDs also alter Na~V~ function, and we compare their relative potencies on Na~V~ and on gA channels as probes of changes in bilayer properties.

The TZDs produce a prepulse-dependent inhibition of peak *I*~Na~ ([Fig. 9 A](#fig9){ref-type="fig"}). This was examined further using an alternating pulse protocol ([@bib71]). See the bottom of [Fig. 9](#fig9){ref-type="fig"}, with conditioning prepulses to either −130 mV (*V*~0~) or to a voltage at which about half the channels are in the fast-inactivated state (*V*~1/2~ ≈ −68 ± 2; see [Fig. 9 B](#fig9){ref-type="fig"}). After ∼5 min of stable baseline recordings using this protocol, the TZDs were applied. The peak *I*~Na~ during the test pulse was strongly reduced by 6 µM troglitazone ([Tables III](#tbl3){ref-type="table"} and [S2](http://www.jgp.org/cgi/content/full/jgp.201010529/DC1)), and the inhibition was stronger after a prepulse potential to *V*~1/2~ than to *V*~0~ ([Fig. 9](#fig9){ref-type="fig"}).

![Effect of troglitazone on Na~V~. (A) Macroscopic Na^+^ current traces elicited with a pulse to 0 mV in control (left panel, black traces) or in the presence of 6 µM troglitazone (TRO, right panel, olive traces) after a 300-ms prepulse to either −130 mV (*V*~0~) or to a voltage at which approximately half of the channels are in the fast-inactivated state (*V*~1/2~ of ≈68 mV). (B) Time course of wash-in and washout of 6 µM troglitazone (TRO) during an alternating pulse protocol applied every 5 s in which the prepulse potential was either *V*~0~ or *V*~1/2~ (see inset for pulse protocol). The currents are normalized to the peak *I*~Na~ in control. Troglitazone inhibits peak *I*~Na~, and the inhibition is larger after a prepulse to *V*~1/2~. The inhibition was fully reversible after washout (2 min) when tested after a prepulse to *V*~0~ mV; the inhibition was only partially reversible when tested after a prepulse to *V*~1/2~ (*n* = 4).](JGP_201010529R_RGB_Fig9){#fig9}

###### 

The effect of TZDs on peak *I*~Na~ and Na~V~ inactivation

  Experimental condition   Inhibition of peak *I*~Na~                                                                                                                                         
  ------------------------ --------------------------------------- ------ --------------------------------------- ------ ----- -------------------------------------- ----- ----- ----------- -----
                           norm *I*~Na~                            SD     norm *I*~Na~                            SD     *n*   *V*~1/2~ (mV)                          SD    *n*   Δ*V*~1/2~   SD
  Control                  1.00                                    \#     1.00                                    \#     7     −68                                    2.3   6     −13         4.1
  6 µM troglitazone        0.62[a](#tblfn4){ref-type="table-fn"}   0.12   0.36[a](#tblfn4){ref-type="table-fn"}   0.13   7     −81[a](#tblfn4){ref-type="table-fn"}   4.8   6                 
  Wash                     0.97                                    0.05   0.79                                    0.08   7     −73[a](#tblfn4){ref-type="table-fn"}   1.8   4                 
  Control                  1.00                                    \#     1.00                                    \#     3     −70                                    1.9   3     −5          1.5
  200 µM rosiglitazone     0.74[b](#tblfn5){ref-type="table-fn"}   0.04   0.60[b](#tblfn5){ref-type="table-fn"}   0.04   3     −76[c](#tblfn6){ref-type="table-fn"}   1.5   3                 
  Wash                     0.97                                    0.01   0.76                                    0.03   3     −76                                    2.1   3                 
  Control                  1.00                                    \#     1.00                                    \#     4     −72                                    2.8   4     −2          0.4
  10 µM pioglitazone       0.97                                    0.02   0.91[b](#tblfn5){ref-type="table-fn"}   0.01   4     −74[b](#tblfn5){ref-type="table-fn"}   2.5   4                 
  Wash                     1.01                                    0.05   0.89                                    0.11   4     −75[c](#tblfn6){ref-type="table-fn"}   3.0   3                 
  Control                  1.00                                    \#     1.00                                    \#     7     −69                                    1.5   4     −3          1.9
  6 µM ciglitazone         0.74[a](#tblfn4){ref-type="table-fn"}   0.03   0.72[a](#tblfn4){ref-type="table-fn"}   0.11   7     −72[c](#tblfn6){ref-type="table-fn"}   0.4   4                 
  Wash                     0.77                                    0.04   0.76                                    0.16   7     −71                                    1.3   4                 
  Control                  n/a                                            n/a                                                  −68                                    2.5   5     0.3         0.8
  Sham drug                n/a                                            n/a                                                  −68                                    2.4   5                 

The TZD effects on peak *I*~Na~ after prepulses to −130 mV (*V*~0~) or to a voltage at which approximately half the channels are in the fast-inactivated state (*V*~1/2~). The currents were measured after 1-min perfusion of the drug. Fractional peak *I*~Na~ was normalized to the control value. Right column of the table shows the effects of TZDs on steady-state inactivation (or Na^+^ channel availability *h*~∞~ in the [@bib50], model). *V*~1/2~ values were determined in control after 1-min perfusion of the drug and after 2-min washout of the drug. All TZDs significantly shifted *V*~1/2~ toward hyperpolarized potentials. Stimulation protocols as described in detail in Materials and methods and can also be seen in [Fig. 10](#fig10){ref-type="fig"}.

P \< 0.001 versus control by paired two-tailed Student's *t* test.

P \< 0.01 versus control by paired two-tailed Student's *t* test.

P \< 0.05 versus control by paired two-tailed Student's *t* test.

The inhibition was fully reversible when tested from *V*~0~, but only partially so when tested from *V*~1/2~ ([Tables III](#tbl3){ref-type="table"} and S2). Similar complete and partial reversibility after prepulses to *V*~0~ or *V*~1/2~, respectively, was observed with rosiglitazone. In contrast, the *I*~Na~ inhibition by ciglitazone (at 6 µM) did not reverse for either conditioning pulse after washout times that were effective for troglitazone and rosiglitazone (2 min). Pioglitazone caused minimal current inhibition (at 10 µM). [Fig. 10](#fig10){ref-type="fig"} compares inhibition of peak *I*~Na~ at the highest concentrations tested, with 6 µM troglitazone being the strongest and 10 µM pioglitazone being the weakest inhibitor.

![The effect of TZDs on Na~V~ steady-state fast inactivation. The left panels show families of Na^+^ current traces recorded using a 10-ms test pulse to 0 mV after 300-ms conditioning prepulses to potentials ranging from −130 to −10 mV (inset shows stimulation protocol) in the absence (black current traces) or presence of the drug (colored current traces). Peak *I*~Na~ was normalized to the maximum peak *I*~Na~ (elicited after a prepulse to −130 mV), plotted against the prepulse potential and fitted with a two-state Boltzmann distribution (right panels) to determine the voltage for half-maximal inactivation (*V*~1/2~). 6 µM troglitazone (TRO, olive traces and symbols; Δ*V*~1/2~ = −13.2 ± 4.1 mV, *n* = 6, and P \< 0.001 vs. control by paired two-tailed Student's *t* test), 200 µM rosiglitazone (ROS, pink traces and symbols; Δ*V*~1/2~ = −5.4 ± 1.5 mV, *n* = 3, and P \< 0.05), 10 µM pioglitazone (PIO, gray traces and symbols; Δ*V*~1/2~ = −2.3 ± 0.4 mV, *n* = 4, and P \< 0.05), and 6 µM ciglitazone (CIG, orange traces and symbols; Δ*V*~1/2~ = −3.0 ± 1.9 mV, *n* = 4, and P \< 0.05).](JGP_201010529R_RGB_Fig10){#fig10}

As in the bilayer experiments, ciglitazone increased the capacitance in the whole cell experiments (6 µM ciglitazone increased the capacitance ∼15%, which was partially reversible after washout; not depicted); the other TZDs had no discernible effect. The ciglitazone-induced capacitance increase most likely reflects intramembrane transfer, as has been observed with other hydrophobic anions ([@bib31]).

### Effects of TZDs on Na~V~ inactivation.

The steady-state inactivation (*h*~∞~ in the [@bib50], model) curve was determined using a double-pulse protocol. All the TZDs produced a hyperpolarizing shift in *V*~1/2~ ([Fig. 10](#fig10){ref-type="fig"} and [Tables III](#tbl3){ref-type="table"} and [S3](http://www.jgp.org/cgi/content/full/jgp.201010529/DC1)). The largest shift was seen with 6 µM troglitazone (−13.2 ± 4.1 mV, *n* = 6, and P \< 0.001 vs. control), followed by 200 µM rosiglitazone (−5.4 ± 1.5 mV, *n* = 3, and P \< 0.05), 6 µM ciglitazone (−3.0 ± 1.9 mV, *n* = 4, and P \< 0.05), and 10 µM pioglitazone (−2.3 ± 0.4 mV, *n* = 4, and P \< 0.01). Timed control experiment, done with the control buffer solution, showed no shift in *V*~1/2~ during perfusion of the drug-free "sham drug" solution and subsequent "sham wash" ([Table III](#tbl3){ref-type="table"} and [Fig. S10](http://www.jgp.org/cgi/content/full/jgp.201010529/DC1)).

To determine whether the TZD-induced changes in Na~V~ function could be related to the TZD-induced changes in gA channel function, we compared changes in *V*~1/2~ ([Fig. 11 B](#fig11){ref-type="fig"}) to relative changes in gramicidin lifetime ([Fig. 11 A](#fig11){ref-type="fig"}) for each compound, as plotted in [Fig. 11 C](#fig11){ref-type="fig"}. The divergent *V*~1/2~--\[TZD\] relations ([Fig. 11, A and B](#fig11){ref-type="fig"}) can be superimposed when using the TZD-induced changes in τ as a measure for the TZD-induced changes in bilayer properties. The *V*~1/2~--\[TZD\] relations can be superimposed on the *V*~1/2~--\[amphiphile\] relations observed previously in studies on capsaicin and various detergents ([@bib72]). The amphiphile-induced changes in Na~V~ (and gA channel) function do not appear to result from direct channel--amphiphile interactions but from altered channel--bilayer interactions.

![Comparison of the TZDs' effects on Na~V~ and gA channels. (A) The concentration dependence of the TZD-induced changes in AgA(15) single-channel lifetimes (τ/τ~cntrl~; *n* = 1--7; mean ± SD). (In the experiment with 15 µM pioglitazone, there was visible precipitation.) (B) The concentration-dependent shifts in *V*~1/2~ for inactivation. (*n* = 2--6; mean ± SD). (C) The TZD-induced shifts in *V*~1/2~ versus the natural logarithm of relative changes in AgA(15) single-channel lifetimes. The Δ*V*~1/2~ versus ln(τ/τ~cntrl~) relations for troglitazone (TRO, olive squares), rosiglitazone (ROS, pink squares), pioglitazone (PIO, gray squares), and ciglitazone (CIG, orange squares) are very similar among the TZDs, as well as to the relations observed previously for other bilayer modifiers: Triton X-100 (TX100), β-octyl glucoside (βOG), reduced Triton X-100 (rTX100), Genapol X-100 (GX100), and capsaicin ([@bib72]).](JGP_201010529_RGB_Fig11){#fig11}

DISCUSSION
==========

TZDs alter gramicidin channel function at concentrations where they alter the function of many membrane proteins, including Na~V~. The changes in Na~V~ function correlate with the changes in gA channel function, following the pattern observed previously for other amphiphiles ([@bib72]; [Fig. 11](#fig11){ref-type="fig"}), suggesting that the TZDs (and the other amphiphiles) alter the function of both channels through a common mechanism. Given that the only common feature of gA and Na~V~ channels is that they are embedded in lipid bilayers, the most likely common mechanism is that the TZDs adsorb to lipid bilayers to alter their properties. As we discuss below, the changes in gA and Na~V~ channel function occur at TZD concentrations that are similar to (for ciglitazone, pioglitazone, and troglitazone) or somewhat higher than (rosiglitazone) the plasma concentrations in patients (or animals) treated with TZDs.

We first discuss the concentrations at which the TZDs alter lipid bilayer properties; TZDs bind to plasma proteins and partition between the electrolyte and bilayer, and the free concentrations will be less than the nominal concentrations. We next consider the changes in gA channel function, as reporters of changes in bilayer properties. We then consider the possible confounding effects of *n*-decane in the planar bilayer experiments. Next, we discuss the changes in Na~V~ channel function and the relationship between the changes in Na~V~ and gA channel function. Finally, we consider how changes in lipid bilayer properties may constitute a general mechanism for the off-target effects of hydrophobic/amphiphilic drugs, including the TZDs.

At what concentrations do the TZDs alter lipid bilayer properties?
------------------------------------------------------------------

The TZDs are hydrophobic, with octanol--water partition coefficients, expressed as clogP or logD~7.4~, between 2.8 and 2.6 (for rosiglitazone) and 5.7 and 4.6 (ciglitazone; legend to [Fig. 1](#fig1){ref-type="fig"}). Thus, they are likely to partition into bilayers and bind to proteins, and the free drug concentration will be less than the nominal concentration ([@bib96]; [@bib16]; [@bib55]).

The TZDs are weak acids, and water--octanol partition coefficients thus may be poor predictors of TZD partitioning into bilayers ([@bib24]; [@bib11]). We therefore measured their partition coefficients (*K*~p~) into lipid bilayers using isothermal titration calorimetry. Troglitazone and rosiglitazone had sufficient partition enthalpy to allow for the determination *K*~p~. The measured log*K*~p~s ([Fig. 8](#fig8){ref-type="fig"}) are close to, but higher than, logD~7.4~. The relationship to clogP is more complicated: for troglitazone, log*K*~p~ \< clogP; for rosiglitazone, log*K*~p~ \> clogP (compare [Fig. 8](#fig8){ref-type="fig"} and legend to [Fig. 1](#fig1){ref-type="fig"}). On balance, the results suggest that one can use logD~7.4~ (and clogP) to estimate the bilayer partition coefficients (see below). (The planar bilayer experiments were done using 1M NaCl, and the vesicle experiments were done using 140 mM NaNO~3~; however, ionic strength effects on pK*~a~* are small \[cf. [@bib45]; [@bib89]\]. Similarly, ionic strength effects on partitioning will be small because we use zwitterionic DC~18:1~PC and rather low TZD concentrations; salting-in or -out effects likewise will be small \[cf. [@bib21]\]. We do not consider these effects further.)

Knowing the partition coefficients, we can estimate the free drug concentrations ([@bib16]; [@bib55]; see [Appendix](#app1){ref-type="sec"}). At the concentrations listed, the mole fractions (*m*~TZD~) are small ([Table IV](#tbl4){ref-type="table"}), at 0.03 or less. The different mole ratio of troglitazone and rosiglitazone needed to alter bilayer properties may reflect that they localize differently in the bilayer--solution interface (as suggested by the different enthalpic and entropic contributions to the free energy of portioning). There are 10 lipids in the first shell around a gA, so there will be less than one TZD in the first shell, unless the TZDs accumulate in the perturbed bilayer adjacent to the channel ([@bib6]; [@bib16]). This is unlikely, at least in the case of ciglitazone, because the conductance changes do not depend on bilayer thickness ([Fig. S11](http://www.jgp.org/cgi/content/full/jgp.201010529/DC1)), indicating that ciglitazone does not partition preferentially into, or out of, the perturbed bilayer region (see also, [@bib16]). Although the *m*~TZD~s are small, the volume-averaged TZD concentrations in the bilayer are high, ranging from 1 to 15 mM.

###### 

TZD concentrations in plasma and in vitro

  TZD             In vivo/clinical                                            Bilayer experiments   Vesicle experiments                                                                             
  --------------- -------------------------------------------- -------------- --------------------- ----------------------------------------- --------------- ------------ -------- --------------- ------------
                  *µM*                                         *nM*           *µM*                  *nM*                                      *moles/cm^2^*                *nM*     *moles/cm^2^*   
  Troglitazone    2--6.4[d](#tblfn10){ref-type="table-fn"}     2--64          1                     80                                        5 × 10^−13^     2 × 10^−3^   130      9 × 10^−13^     4 × 10^−3^
  Rosiglitazone   0.4--1.7[d](#tblfn10){ref-type="table-fn"}   4--17          30                    18,000                                    6 × 10^−12^     2 × 10^−2^   22,100   8 × 10^−13^     3 × 10^−2^
  Pioglitazone    1.5--4.4[e](#tblfn11){ref-type="table-fn"}   36             10                    5,600[f](#tblfn12){ref-type="table-fn"}   2 × 10^−12^     10^−2^       6,900    3 × 10^−12^     10^−2^
  Ciglitazone     37--90[g](#tblfn13){ref-type="table-fn"}     1,900--2,700   1                     5[f](#tblfn12){ref-type="table-fn"}       5 × 10^−13^     2 × 10^−3^   9        10^−12^         4 × 10^−3^

Estimated based on protein binding.

\[TZD\] where gA channel function is altered.

Estimated as described in Eqs. [A7](#fda7){ref-type="disp-formula"}--[A9](#fda9){ref-type="disp-formula"}.

FDA (five of the links where the information can be accessed).

[@bib109].

Based on clogP (legend to [Fig. 1](#fig1){ref-type="fig"}).

[@bib100], and [@bib2]; values for rats.

To compare with clinical concentrations, [Table IV](#tbl4){ref-type="table"} lists literature values for the total and free TZD concentrations in vivo and in vitro. For troglitazone and ciglitazone, the total and free plasma concentrations are similar to those in the bilayer experiments. For rosiglitazone, the concentrations in the bilayer experiments are higher than the plasma concentrations.

Changes in gA channel function and in bilayer properties
--------------------------------------------------------

Gramicidin channels form by transbilayer dimerization of subunits in opposing bilayer leaflets ([@bib83]), which make them suitable to probe for changes in bilayer properties ([@bib73]). gA channel function, specifically the channel appearance frequency and lifetime, depends on how easy it is to deform the bilayer when the channel forms. The less energy required for bilayer deformation, the more likely it is that monomer encounters will result in successful dimerization, and the smaller will be the disjoining force acting on the bilayer-spanning dimer.

Many amphiphiles, including the TZDs, alter gA channel appearance frequencies and lifetimes (see [@bib73]), meaning that they alter lipid bilayer properties when they adsorb at the bilayer--solution interface. The common relation between the relative increases in τ for the gA^−^(13) and AgA(15) channels caused by troglitazone, rosiglitazone, ciglitazone, and other bilayer-modifying amphiphiles ([@bib74]; [Fig. 6](#fig6){ref-type="fig"}) indicates that these compounds alter gA channel lifetimes by a common mechanism that does not involve specific binding.

Ciglitazone's effects are more complex ([Figs. 3](#fig3){ref-type="fig"} and [5](#fig5){ref-type="fig"}). Yet, the ciglitazone-induced changes in τ follow a simple pattern ([Figs. 5 D](#fig5){ref-type="fig"} and [6](#fig6){ref-type="fig"}). First, in DC~20:1~PC bilayers, ciglitazone causes a greater increase in τ for the shorter AgA^−^(15) compared with the longer gA(17) channels (Fig. S6). Second, the increase in τ of AgA^−^(15) channels in DC~20:1~PC/*n*-decane bilayers is greater than the increase in AgA(15) channels in DC~18:1~PC/*n*-decane bilayers ([Figs. 5 D](#fig5){ref-type="fig"} and S6), meaning that the increase in τ depends on the channel--bilayer hydrophobic mismatch. Third, ciglitazone alters τ of both AgA(15) and AgA^−^(15) channels ([Figs. 5 D](#fig5){ref-type="fig"} and S6). Ciglitazone's effects on τ vary with hydrophobic mismatch, not the detailed channel structure, indicating that it alters τ through increases in bilayer elasticity.

Troglitazone, rosiglitazone, and pioglitazone increased *f*; ciglitazone decreased *f*. The changes in lifetimes and appearance frequencies caused by troglitazone and rosiglitazone follow the pattern observed for other amphiphiles (unpublished data), meaning that these molecules shift the monomer--dimer equilibrium toward the dimer and thus reduce $\Delta G_{\text{bil}}^{\text{M}\rightarrow\text{D}}$ ([Table II](#tbl2){ref-type="table"}). Pioglitazone did not change τ, indicating that it does not alter bilayer elasticity at attainable concentrations. It does, however, increase *f* for both the left-handed gA^−^(13) and the right-handed gA channels, which could be because of a shift between β^6.3^-helical and non--β^6.3^-helical monomers (by a mechanism that does not involve direct gramicidin--pioglitazone interactions, as pioglitazone is completely inert in cholesterol-containing bilayers; Fig. S7). Ciglitazone also has complex effects. The decreases in *f* ([Figs. 3](#fig3){ref-type="fig"} and [5 G](#fig5){ref-type="fig"}) indicate that it alters gA channel function by a mechanism not involving changes in bilayer elasticity. Ciglitazone does not appear to interact with the β^6.3^-helical dimers (channels); however, nor does it alter the equilibrium between single-stranded and double-stranded dimers in SEC experiments (Kapoor, R., personal communication). SEC experiments, however, are done at high gA/lipid ratios (1:20--1:100; [@bib13]), where all gA is dimeric, and do not provide information about monomers. The decreases in *f* are observed at gA/lipid mole ratios at ∼1:10^6^, where gA is mostly monomeric ([@bib20]). Although bilayer-embedded gA monomers are β^6.3^ helical at high gA/lipid ratios ([@bib46]), maybe ciglitazone shifts the distribution among the monomers toward non--β^6.3^-helical conformers at low gA /lipid ratios.

To check whether the changes in the gA monomer↔dimer equilibrium could be solely the result of changes in bilayer elasticity, we compare two different approaches to estimate $\Delta G_{\text{bil}}^{\text{M}\rightarrow\text{D}}.$ Based on the changes in τ and using [Eq. 11](#fd11){ref-type="disp-formula"}, 1 µM troglitazone and 30 µM rosiglitazone decrease *H*~B~ by ∼1.5 kJ/(mol·nm^2^) or ∼0.6 *k*~B~*T*/nm^2^. Although small in relation to *H*~B~, 56 kJ/(mol·nm^2^) or 22 *k*~B~*T*/nm^2^ ([@bib73]), these changes in *H*~B~ are sufficient to account for the measured changes in $\Delta G_{\text{bil}}^{\text{M}\rightarrow\text{D}}.$ The hydrophobic mismatch-dependent contribution to $\Delta G_{\text{bil}}^{\text{M}\rightarrow\text{D}}\left( {= \left( H_{\text{B}} - H_{\text{B,cntrl}} \right) \cdot \left( l - d_{0} \right)^{2}} \right)$ then can be estimated from the changes in *H*~B~, knowing that *d*~0~ is unchanged (see Results) ([Fig. 12](#fig12){ref-type="fig"}). This estimate for $\Delta G_{\text{bil}}^{\text{M}\rightarrow\text{D}}$ can be compared with changes in $\Delta G_{\text{bil}}^{\text{M}\rightarrow\text{D}}$ estimated using the time-averaged channel concentrations and [Eq. 4](#fd4){ref-type="disp-formula"} ([Table II](#tbl2){ref-type="table"}).

![The troglitazone- (TRO, olive bars) or rosiglitazone- (ROS, pink bars) induced changes in the bilayer deformation energy, as determined from the changes in *H*~B~ (the hydrophobic mismatch--dependent term in [Eq. A4](#fda4){ref-type="disp-formula"}). 1 µM troglitazone and 30 µM rosiglitazone (*n* = 4--6).](JGP_201010529R_RGB_Fig12){#fig12}

For AgA(15) channels, *l* = 2.2 nm (Table S1) and *d*~0~ ≈ 4.0 nm ([@bib74]), and the $\left( H_{\text{B}} - H_{\text{B,cntrl}} \right) \cdot \left( l - d_{0} \right)^{2}$ contribution is estimated to be −4 to −7 (kJ/mol), comparable to the −4 (kJ/mol) calculated from changes in time-averaged dimer concentrations ([Table II](#tbl2){ref-type="table"}). For gA^−^(13) channels, *l* = 1.9 nm (Table S1), and the $\left( H_{\text{B}} - H_{\text{B,cntrl}} \right) \cdot \left( l - d_{0} \right)^{2}$ contribution is estimated to be −5 to −9 kJ/(mol·nm^2^), somewhat larger than the estimates in [Table II](#tbl2){ref-type="table"}. The effects of troglitazone and rosiglitazone can be accounted for by changes in bilayer elasticity.

Adding cholesterol to the bilayer-forming solution altered the TZD bilayer-modifying potency: troglitazone's was increased---both the lifetime and appearance rate changes were larger in the cholesterol-containing bilayers (Fig. S7); pioglitazone's was decreased---neither τ nor *f* was altered, suggesting that the pioglitazone-induced increases in *f* are not a result of specific interactions with the gramicidins. Changes in bulk membrane properties alter the TZDs' efficacy, although the direction of the changes in efficacy may vary.

The TZDs have similar effects in hydrocarbon-containing and hydrocarbon-free bilayers
-------------------------------------------------------------------------------------

TZDs alter lipid bilayer properties in both hydrocarbon-containing planar bilayers and hydrocarbon lipid vesicles (compare [Figs. 5](#fig5){ref-type="fig"}, [6](#fig6){ref-type="fig"}, and [7](#fig7){ref-type="fig"}). The effective concentration ranges and relative potencies were similar in planar bilayers ([Figs. 5](#fig5){ref-type="fig"} and [6](#fig6){ref-type="fig"}), decane-free large unilamellar vesicles ([Fig. 7](#fig7){ref-type="fig"}), and in biological membrane as reported by changes in Na~V~ channel function ([Fig. 11](#fig11){ref-type="fig"}).

This is not surprising. *n*-Decane--containing planar bilayers are softer than nominally hydrocarbon-free bilayers ([@bib69]), but the ln{τ}--*d*~0~ relations in planar bilayers are linear ([@bib69]; [@bib73]), meaning that *F*~dis~ is a linear function of *d*~0~ − *l* (cf. [Eq. A5](#fda5){ref-type="disp-formula"}). That is, the expression for $\Delta G_{\text{bil}}^{\text{M}\rightarrow\text{D}}$ includes a term that is quadratic in *d*~0~ −*l* (cf. [Eq. A4](#fda4){ref-type="disp-formula"}). We further note that the lipid intrinsic curvature usually is determined in x-ray scattering experiments on lipid--hydrocarbon systems ([@bib101]; [@bib17]), and that the hydrocarbons have relatively little effect on the measured values ([@bib17]). (*n*-Decane--containing planar bilayers are under tension \[e.g., [@bib22]\], whereas the lipid vesicles used in the fluorescence experiments may not be. gA channel lifetimes, however, are little affected by changes in membrane tension per se \[[@bib51]; [@bib40]\], although channel function may be altered by tension-dependent changes in bilayer thickness \[[@bib40]\].)

Changes in Na~V~ channel function
---------------------------------

Previous studies have shown that troglitazone is a more potent modifier of ion channel function than the other TZDs ([Table I](#tbl1){ref-type="table"}). Few studies, however, have compared different TZDs' effects on the same system. We therefore compared the effects of the four TZDs on the activity of endogenous Na~V~ channels in a mammalian cell line. The TZDs inhibit peak currents and shift the *V*~1/2~ for inactivation in the hyperpolarizing direction. Timed control experiments using a similar perfusion and pulse protocol as was used with the TZDs cause minimal changes in *V*~1/2~ ([Table III](#tbl3){ref-type="table"} and Fig. S10). Except for ciglitazone, the inhibition is reversible when the test currents are measured after a prepulse to −130 mV, and we cannot exclude that ciglitazone interacts directly with Na~V~, in addition to altering bilayer properties. When the currents are measured after a prepulse to *V*~1/2~, the inhibition is not fully reversible, presumably reflecting that the shift in *V*~1/2~ is not fully reversible. Maybe the TZDs accelerate the hyperpolarizing shift in *V*~1/2~ that occurs in whole cell voltage-clamp studies (e.g., [@bib32]; [@bib104]). In any case, the TZDs shift the equilibrium distribution between noninactivated (closed or open) and inactivated states toward the inactivated state(s). (The TZDs also alter Na~V~ activation \[[Table S4](http://www.jgp.org/cgi/content/full/jgp.201010529/DC1)\] as well as the time course of inactivation and recovery from inactivation. These changes will be the focus of a forthcoming article \[unpublished data\].)

Because of redistribution between the aqueous solution and the membrane and other hydrophobic compartments, the free aqueous \[TZD\] may differ between the bilayer system and the whole cell voltage-clamp system ([@bib96]; [@bib16]; [@bib55]; [@bib39]). Yet, troglitazone and rosiglitazone alter Na~V~ function ([Fig. 11 B](#fig11){ref-type="fig"}) at the same nominal concentrations and with the same order of potency as gA function ([Fig. 11 A](#fig11){ref-type="fig"}). When plotting the hyperpolarizing shift of *V*~1/2~ versus the change in gA lifetime ([Fig. 11 C](#fig11){ref-type="fig"}), the relationship between the changes in Na~V~ function and gA channel lifetime is remarkably similar---and not just among the TZDs but also among other bilayer-modifying compounds. This commonality suggests that these structurally diverse compounds alter both Na~V~ and gA channel function through a common mechanism that involves changes in bilayer properties. This does not exclude more direct drug channel interactions, for example, at the channel--bilayer boundary ([@bib4]), that also may alter the energetic coupling between lipid bilayers and their embedded proteins. Detergents ([@bib19]) and small amphiphiles ([@bib82]), for example, can bind at the protein--bilayer interface, which means that they can alter protein function by altering the energetic coupling between the bilayer and its embedded ion channels. We conclude that the TZDs alter the equilibrium between noninactivated (closed or open) and inactivated Na~v~ states by changing the bilayer elasticity (the bilayer deformation energy associated with the transition into the inactivated state). That is, the bilayer becomes an allosteric regulator of Na~V~ function.

The lipid bilayer as a mediator of off-target drug effects: implications for drug development
---------------------------------------------------------------------------------------------

Our results suggest that gA channels can be used to "predict" whether amphipathic/hydrophobic molecules are likely to perturb membrane protein function, and at what concentrations. The correlation between the changes in gA channel lifetimes and the shift in the *V*~1/2~ for Na~V~ inactivation is remarkable considering that Na~V~ channels are structurally and functionally very different from gA channels. This ability to predict changes in Na~V~ channel function from changes in gA function suggests that ion channel (membrane protein) function is regulated by changes in bilayer properties, including adaptations in the lipids in immediate contact with the protein, strengthening the conclusions of previous studies ([@bib72]; [@bib9]; [@bib96]).

The TZDs were discovered in a search for hypolipidemic clofibrate-type compounds ([@bib52]). Ciglitazone was the first TZD to be explored for clinical use; it was discontinued during Phase II trials ([@bib91]). It was followed by troglitazone, rosiglitazone, and pioglitazone, the three TZDs actually marketed as insulin sensitizers. Roglitazone was later withdrawn ([@bib91]), and rosiglitazone is restricted in the United States ([@bib33]) and suspended in Europe ([@bib25]).

The TZDs modify lipid bilayer properties with the order of potency, troglitazone \> ciglitazone \> rosiglitazone ≥ pioglitazone, which differs from their hydrophobicity (legend to [Fig. 1](#fig1){ref-type="fig"}), ciglitazone \> troglitazone \> pioglitazone \> rosiglitazone, and their affinity for PPARγ ([Table I](#tbl1){ref-type="table"}). Ciglitazone and troglitazone are the most potent gA channel and Na~V~ modifiers---and the most hydrophobic. The concentrations where troglitazone alters gA channel function are similar to the clinical plasma concentrations ([Table IV](#tbl4){ref-type="table"}). Troglitazone alters the function of many membrane proteins at concentrations where it alters bilayer properties ([Table I](#tbl1){ref-type="table"}), and some of its PPARγ-independent effects, such as vasorelaxation and acute glucose uptake ([@bib35]; [@bib77]; [@bib34]), could arise from its bilayer-modifying effects. Troglitazone's bilayer-modifying properties also could account for its hepatotoxicity that may be a result of inhibition of hepatic bile acid transport ([@bib95]).

Rosiglitazone and pioglitazone, which have the least clogP and logD~7.4~, are the least bilayer modifying. Pioglitazone, the least potent bilayer modifier, has less cardiovascular side effects than rosiglitazone ([@bib41]; [@bib57]; [@bib81]). Rosiglitazone's clinical side effects, however, occur at concentrations where it has minimal bilayer-modifying effects (compare [Table IV](#tbl4){ref-type="table"}). The bilayer-modifying potency of TZDs, as expressed in changes in gA channel function, can be used to predict the likelihood and severity of side effects at the TZDs' plasma concentrations during treatment. But these drugs do, of course, also cause side effects through mechanisms unrelated to their bilayer effects.

The TZDs are part of a growing library of molecules that alter gA channel function (e.g., [@bib73]). It has long been known that hydrophobic drugs have "membrane effects" (e.g., [@bib94]), and the bilayer-perturbing effects of hydrophobic drugs have been characterized using a variety of physicochemical probes ([@bib92]). It has proven difficult, however, to relate changes in bilayer properties, as deduced from changes in some physicochemical probes, to changes in membrane protein function, and the changes in bilayer properties may not be causally related to the changes in protein function ([@bib97]). Many of these difficulties can be overcome using gA channels to "sense" aggregate changes in bilayer properties and report them as changes in bilayer deformation energy (or the disjoining force acting on the channels). This is important because bilayer-spanning membrane proteins are energetically coupled to their host bilayer through hydrophobic interactions, meaning that there will be a bilayer contribution to the energetics (and kinetics) of protein conformational changes that involve the protein--bilayer boundary, which provides for mechanistic insights into hydrophobic drugs' "membrane effects."

The ability of hydrophobic drugs to alter membrane protein function correlates with their ability to alter gA channel function ([Fig. 11](#fig11){ref-type="fig"}), making it possible to explore a drug candidate's bilayer-perturbing potential early in product development ([@bib65]; [@bib67]). It is not sufficient to focus just on hydrophobicity ("lipophilicity" in the drug development literature), because hydrophobicity per se may not predict a compound's bilayer-modifying potential, as evident in our results and from a previous study showing that oleic acid has a higher bilayer partition coefficient than docosahexaenoic acid, yet docosahexaenoic acid is the more potent bilayer modifier ([@bib16]). A drug must be sufficiently hydrophobic to reach its target ([@bib66]), and too high hydrophobicity is likely to be problematic because the drug may partition strongly into lipid bilayers, but increased hydrophobicity cannot be equated with increased bilayer-modifying propensity. It is important to explicitly test whether a drug lead is a bilayer modifier using probes that sense relevant (for membrane proteins) changes in bilayer properties, such as the gA channels.

APPENDIX {#app1}
========

Energetics of lipid bilayer deformations
----------------------------------------

The bilayer deformation energy ($\Delta G_{\text{def}}$) associated with a local bilayer thinning can be expressed as:$$\Delta G_{\text{def}} = H_{\text{B}} \cdot \left( l - d_{0} \right)^{2} + H_{\text{X}} \cdot \left( l - d_{0} \right) \cdot c_{0} + H_{\text{C}} \cdot c_{0}^{2},$$where *H*~B~, *H*~X~, and *H*~C~ are elastic coefficients that are functions of bilayer thickness, elastic moduli, and channel radius (and include contributions from the energetic cost of redistributing the different components in multi-component membranes, including redistribution of the decane in our planar bilayers), and *c*~0~, the intrinsic monolayer curvature ([@bib79]).

[Eq. A1](#fda1){ref-type="disp-formula"} can be derived from the theory of elastic bilayer deformations ([@bib79]; cf. their Eq. 17). The biquadratic structure of [Eq. A1](#fda1){ref-type="disp-formula"} applies more generally, however ([@bib5]). Membrane protein function is regulated by experimental maneuvers that alter bilayer thickness and intrinsic lipid curvature ([@bib5]; [Tables I](#tbl1){ref-type="table"} and [II](#tbl2){ref-type="table"}), meaning that $\Delta G_{\text{def}}^{\text{0}}$ can be expressed as a function of (*l* − *d*~0~) and *c*~0~, and maybe other terms. Using a Taylor expansion in (*l* − *d*~0~) and *c*~0~, $\Delta G_{\text{def}}^{\text{0}}$ becomes:$$\begin{matrix}
{\Delta G_{\text{def}}^{\text{0}}\left( l - d_{0},c_{0} \right) = \Delta G_{\text{def}}^{\text{0}}\left( 0,0 \right) + \frac{\partial\left( \Delta G_{\text{def}}^{\text{0}} \right)}{\partial\left( l - d_{0} \right)} \cdot \left( l - d_{0} \right)} \\
{+ \frac{\partial\left( \Delta G_{\text{def}}^{\text{0}} \right)}{\partial c_{0}} \cdot c_{0} + \frac{1}{2}\frac{\partial^{2}\left( \Delta G_{\text{def}}^{\text{0}} \right)}{\partial\left( l - d_{0} \right)^{2}} \cdot \left( l - d_{0} \right)^{2}} \\
{+ \frac{\partial^{2}\left( \Delta G_{\text{def}}^{\text{0}} \right)}{\partial\left( l - d_{0} \right)\partial c_{0}} \cdot \left( d_{0} - l \right) \cdot c_{0} + \frac{1}{2} \cdot \frac{\partial^{2}\left( \Delta G_{\text{def}}^{\text{0}} \right)}{\partial c_{0}^{2}} \cdot c_{0}^{2} + \ldots,} \\
\end{matrix}$$where the first-order terms will be zero when the bilayer can be approximated as an elastic body. (The deformation energy for small decreases in (*d*~0~ − *l*) should equal that for small increases of equal magnitude, with a similar argument holding for *c*~0~.) The biquadratic form of $\Delta G_{\text{def}}^{\text{0}}$ in [Eq. A1](#fda1){ref-type="disp-formula"} thus should be valid quite generally, assuming $\Delta G_{\text{def}}^{0}\left( {0,0} \right)$ = 0, with (keeping the sign convention for the *H* coefficients as in [@bib73], Eq. 2.6):$$H_{\text{B}} = \frac{1}{2} \cdot \frac{\partial^{2}\left( \Delta G_{\text{def}}^{\text{0}} \right)}{\partial\left( l - d_{0} \right)^{2}}, H_{\text{X}} = \frac{\partial^{2}\left( \Delta G_{\text{def}}^{\text{0}} \right)}{\partial\left( l - d_{0} \right)\partial c_{0}}, {and} H_{\text{C}} = - \frac{1}{2} \cdot \frac{\partial^{2}\left( \Delta G_{\text{def}}^{\text{0}} \right)}{\partial c_{0}^{2}}.$$

In multi-component bilayers, the derivatives in Eqs. [A2](#fda2){ref-type="disp-formula"} and [A3](#fda3){ref-type="disp-formula"} include contributions from the redistribution of bilayer components, whether it be lipids or hydrocarbon, meaning that [Eq. A1](#fda1){ref-type="disp-formula"} should apply also for hydrocarbon-containing lipid bilayers, which can be approximated as elastic bodies ([@bib107]; [@bib106]; [@bib28]; [@bib87]).

In [Eq. A1](#fda1){ref-type="disp-formula"}, the $- H_{\text{C}} \cdot c_{0}^{2}$ term is the deformation energy associated with embedding an inclusion of length *d*~0~ (no hydrophobic mismatch) in a bilayer with intrinsic lipid curvature *c*~0~, because of the need for the lipids to adapt to the channel. As noted by [@bib30], this expression does not include the loss of conformational entropy of the acyl chains adjacent to the channel. Using Eqs. [A2](#fda2){ref-type="disp-formula"} and [A3](#fda3){ref-type="disp-formula"}, the corresponding expression becomes ${{\Delta G_{\text{def}}^{0}\left( {0,0} \right) + 1}/2} \cdot \left( {{\partial^{2}\left( \Delta G_{\text{def}}^{\text{0}} \right)}/{\partial c_{0}^{2}}} \right) \cdot c_{0}^{2},$ where $\Delta G_{\text{def}}^{0}\left( {0,0} \right)$ is the energetic cost of embedding an inclusion of length *d*~0~ in a bilayer with *c*~0~ = 0, including the loss of conformational entropy. Whether using [Eq. A1](#fda2){ref-type="disp-formula"} or Eqs. [A2](#fda2){ref-type="disp-formula"} and [A3](#fda3){ref-type="disp-formula"}, the $- H_{\text{C}} \cdot c_{0}^{2}$ term (in [Eq. A1](#fda1){ref-type="disp-formula"}) or ${{\Delta G_{\text{def}}^{0}\left( {0,0} \right) + 1}/2} \cdot \left( {{\partial^{2}\left( \Delta G_{\text{def}}^{\text{0}} \right)}/{\partial c_{0}^{2}}} \right) \cdot c_{0}^{2}$ (in Eqs. [A2](#fda2){ref-type="disp-formula"} and [A3](#fda3){ref-type="disp-formula"}) drops out in the expression for $\Delta G_{\text{bil}}^{\text{M}\rightarrow\text{D}}:$$$\Delta G_{\text{bil}}^{\text{M}\rightarrow\text{D}} = H_{\text{B}} \cdot \left( {l - d_{0}} \right)^{2} + H_{\text{X}} \cdot \left( {l - d_{0}} \right) \cdot c_{0}.$$The bilayer responds to the deformation by imposing a disjoining force (*F*~dis~) on the channel ([@bib5]; [@bib73]):$$F_{\text{dis}} = - \frac{\partial\Delta G_{\text{def}}}{\partial\left( {d_{0} - l} \right)} = 2 \cdot H_{\text{B}} \cdot \left( {d_{0} - l} \right) - H_{\text{X}} \cdot c_{0},$$and changes in *F*~dis~---as a result, for example, of the adsorption of TZDs at the bilayer--solution interface---will be observable as changes in τ:$$\frac{\tau_{\text{TZD}}}{\tau_{\text{cntrl}}} = \exp\left\{ {- \frac{\left( {F_{\text{dis,TZD}} - F_{\text{dis,cntrl}}} \right) \cdot \delta}{k_{\text{B}}T}} \right\},$$where δ (δ \<\< *d*~0~ − *l*) is the distance the two monomers move apart to reach the transition state for channel dissociation.

*F*~dis~ varies as a function of the channel--bilayer hydrophobic mismatch (*l* − *d*~0~) and intrinsic curvature *c*~0~, as well as the elastic moduli as expressed through the *H* coefficients. These contributions are separable, within the framework provided by [Eq. A3](#fda3){ref-type="disp-formula"}, making it possible to further explore the TZD-induced changes in bilayer properties, in particular, whether the changes in bilayer properties reflect changes in intrinsic curvature or elasticity. For example, if the TZDs cause larger relative changes in τ for the shorter than for the longer channels, the changes in *F*~dis~ result, at least in part, from changes in the hydrophobic mismatch-dependent term in [Eq. A5](#fda5){ref-type="disp-formula"}. Conversely, if the TZDs cause similar relative changes in τ of the shorter and longer channels, the changes in *F*~dis~ result primarily from changes in the curvature-dependent term in [Eq. A5](#fda5){ref-type="disp-formula"}.

Free drug concentrations
------------------------

Let {TZD}~m~ denote the \[TZD\] in each leaflet of the membrane (in moles/area) and \[TZD\]~a~ the aqueous \[TZD\]:$$\left\{ \text{TZD} \right\}_{\text{m}} = K_{\text{p}} \cdot \frac{d_{0}}{2} \cdot \left\lbrack \text{TZD} \right\rbrack_{\text{a}}.$$Disregarding TZD adsorbed to the chamber, the conservation relation for the TZD becomes:$$\left\lbrack \text{TZD]} \right._{\text{nom}} \cdot V_{\text{aq}} = \left\lbrack \text{TZD]} \right._{\text{a}} \cdot V_{\text{aq}} + \left\lbrack \text{TZD]} \right._{\text{m}} \cdot V_{\text{lip}},$$where \[TZD\]~nom~ is the nominal \[TZD\] added to the aqueous solutions, *V*~aq~ is the aqueous volume, and *V*~lip~ is the volume of the lipid-forming solution. Combining Eqs. [A7](#fda7){ref-type="disp-formula"} and [A9](#fda9){ref-type="disp-formula"}:$$\left\{ \text{TZD\}} \right._{\text{m}} = \frac{d_{0}}{2} \cdot \left\lbrack \text{TZD]} \right._{\text{m}} = \frac{K_{\text{p}} \cdot \left\lbrack \text{TZD]} \right._{\text{nom}} \cdot V_{\text{aq}} \cdot d_{0}}{\left( {V_{\text{aq}} + K_{\text{p}} \cdot V_{\text{lip}}} \right) \cdot 2}.$$In our case, *V*~aq~ = 5 ml, *V*~lip~ ≈ 2 µl, and *d*~0~ ≈ 4 nm ([Table IV](#tbl4){ref-type="table"}). As we could not determine *K*~p~ for pioglitazone and ciglitazone, we approximate it using clogP.
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